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1 Zusammenfassung 
Das Ziel dieser Arbeit war es, die Expression und Funktion der 
Methylthioadenosinphosphorylase (MTAP) in chronischen Lebererkrankungen zu 
analysieren. 
Es zeigte sich, dass die MTAP mRNA und Proteinexpression in Hepatozyten im 
murinen Fibrosemodell sowie in Zirrhosepatienten vermindert vorliegt, während 
das Substrat 5'-Deoxy-5'-(Methylthio)adenosin (MTA) akkumuliert. Im Gegensatz 
dazu zeigen aktivierte hepatische Sternzellen (HSZ) starke MTAP Expression in 
zirrhotischen Lebern. Darüber hinaus konnte in den aktivierten HSZ im Vergleich 
zu Hepatozyten auch eine erhöhte Menge an intrazellulärem MTA nachgewiesen 
werden. Des weiteren ergab sich eine Korrelation der Collagen I Expression und 
der hepatischen MTA Spiegel in humanen Lebern von Patienten, die an einer 
nichtalkoholischen Steatohepatitis (NASH) litten, was darauf hinweist, dass die 
HSZ einen entscheidenden Beitrag zu den erhöhten MTA Spiegeln in den 
chronisch erkrankten Lebern leisten. Die Suppression von MTAP mittels siRNA in 
HSZ führte zu einer intrazellulären Akkumulation von MTA sowie einer Induktion 
von NFκB und erhöhter Apoptoseresistenz, während die Überexpression zu 
gegenteiligen Ergebnissen führte. Die anti-apoptotischen Effekte einer niedrigen 
MTAP Expression und demzufolge erhöhten MTA Spiegeln korrelierten mit der 
Expression von Survivin. Der anti-apoptotische Effekt wurde durch Inhibition von 
Survivin wieder aufgehoben. Behandlung mit einem demethylierenden Agens 
führte zu einer Induktion der MTAP und zu einer Reduktion der Survivin 
Expression, während, auf der anderen Seite die Stimulation mit reaktiven 
Sauerstoff Spezies (ROS) die Expression von MTAP verminderte und Survivin 
induzierte.  
Zusammenfassend kann man sagen, dass die durch MTAP vermittelte Regulation 
von MTA den Polyaminstoffechsel mit der Apoptose von HSZ in Zusammenhang 
bringt. MTAP selbst sowie Mechanismen, die MTAP modulieren, erscheinen als 
vielversprechende prognostische Marker und therapeutische Angriffspunkte für die 
Behandlung von hepatischer Fibrose. 
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2 Summary 
Objective: To study expression and function of methylthioadenosine 
phosphorylase (MTAP), the rate-limiting enzyme in the methionine and adenine 
salvage pathway, in chronic liver disease. 
Design: MTAP expression was analyzed by qRT-PCR, Western blot and 
immunohistochemical analysis. Levels of MTA were determined by liquid 
chromatography-tandem mass spectrometry. 
Results: MTAP was downregulated in hepatocytes in murine fibrosis models and 
in patients with chronic liver disease, leading to a concomitant increase in MTA 
levels. In contrast, activated hepatic stellate cells (HSCs) showed strong MTAP 
expression in cirrhotic livers. However, also MTA levels in activated HSCs were 
significantly higher than in hepatocytes, and there was a significant correlation 
between MTA levels and collagen expression in diseased human liver tissue 
indicating that activated HSCs significantly contribute to elevated MTA in diseased 
livers. MTAP suppression by siRNA resulted in increased MTA levels, NFκB 
activation and apoptosis resistance, while overexpression of MTAP caused the 
opposite effects in HSCs. The anti-apoptotic effect of low MTAP expression and 
high MTA levels, respectively, was mediated by induced expression of survivin, 
while inhibition of survivin abolished the anti-apoptotic effect of MTA on HSCs. 
Treatment with a DNA demethylating agent induced MTAP and reduced survivin 
expression, while oxidative stress reduced MTAP levels but enhanced survivin 
expression in HSCs.  
Conclusion: MTAP mediated regulation of MTA links polyamine metabolism with 
NFκB activation and apoptosis in HSCs. MTAP and MTAP modulating 
mechanisms appear as promising prognostic markers and therapeutic targets for 
hepatic fibrosis. 
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3 Introduction 
3.1 Liver function and physiology in health and disease 
3.1.1 Liver Anatomy 
Being the largest parenchymal organ and the largest gland in the body gives the 
liver special duties and responsibilities such as protein synthesis and 
detoxification. It is located in the right upper quadrant in the abdominal cavity and 
weighs about 1500 to 2000g. Macroscopically the liver can be divided into four 
lobes naming: Lobus hepatis dexter, Lobus hepatis sinister, Lobus quadratus, and 
Lobus caudatus. Connective tissue, namely Glisson's capsule surrounds the four 
lobes and is linked to intrahepatic tissue.  
Arteria hepatica propria delivers arterial, oxygenated blood and the vena portae 
hepatis supplies venous, nutrient rich blood from the gastrointestinal tract. Liver 
sinusoids manage blood efflux by the Vena hepatica and the Vena cava inferior. 
The liver can be subdivided microscopically in eight segments which are 
consisting of lobuli hepatis which are 1-2mm of size and mainly containing 
hepatocytes with a vein in the center (Vena centralis).  
 
Figure 3.1 Schematical liver architecture (modified from Wissen Media Verlag GmbH, 
München). 
 
In the contact area of several lobules the periportal field includes Arteria and Vena  
interlobularis, as well as bile ducts (Ductuli interlobulares) also known as Glisson’s  
triangle. The bulk cellular mass in the liver is represented by hepatocytes which 
are divided by sinusoids, built by fenestrated, discontinuous endothelium without 
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basal membrane. Specialized macrophages called Kupffer cells are sitting in the 
sinusoids' walls. The space of Disse is called a 10 to 15µM wide perisinusoidal 
space which is located between hepatocytes and sinusoids containing blood 
plasma and hepatic stellate cells (HSCs, also called Ito cells). HSCs store lipids 
and vitamin A. Sinusoidal endothelial cells as well as Kupffer cells and HSCs are 
non parenchymatic cells and represent about 6% cellular volume while 94% of 
cellular mass constitute hepatocytes.  
Hepatocyte
Hepatic stellate cells
Sinusoidal endothelial cells
Kupffer cells
Sinusoidal lumen
 
Figure 3.2 Schematical representation of hepatic cellular components (modified from 
Bataller and Brenner, 2005) 
3.1.2 Liver Function 
The liver represents the most important central organ concerning metabolism. 
Production of essential proteins salvaging carbohydrates and lipids, production of 
bile represent special tasks of the liver and herewith degradation and excretion of 
products of metabolism. Especially carbohydrate metabolism plays an important 
role so it regulates blood glucose concentration independent of food intake via 
gluconeogenesis and glucogenolysis. The liver is further responsible for the 
generation of albumin, globulin and coagulation factors (fibrinogen, prothrombin). 
Lipid metabolism is mediated via building up fatty acids and triglycerides 
(lipogenesis) and vice versa lipids are broken down to free fatty acids and glycerol 
(lipolysis). Synthesis of cholesterol and bile acid derivatives is further mediated by 
the liver. One of the most important tasks is detoxification of endo- and exogenic 
toxins which are metabolized to be discarded via bile or kidneys. During the 
degradation of amino acids ammonia is generated and will be used for the 
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synthesis of urea. Additional functions of the liver are biotransformation of 
xenobiotica and for example heme and storage of iron. By contrast to other organs 
the liver has the ability to regenerate but as a consequence of chronic liver 
disease this capability can be limited. 
3.2 Chronic liver disease 
Liver disease can be classified into acute and chronic liver disease. Acute 
infections or intoxications can be the cause of acute liver injury. This rarely results 
in complete liver failure thanks to the regenerative response of the liver. 
Development of chronic liver disease upon sustaining hepatic injury is 
characterized by chronic hepatic inflammation which can contribute to liver fibrosis 
and ultimately cirrhosis. 
3.2.1 Fibrosis 
Hepatic fibrosis describes an exuberant wound-healing response to chronic liver 
injury associated by hepatocellular damage, inflammation and continuous tissue 
remodeling (Bataller and Brenner, 2001; Bataller and Brenner, 2005; Friedman, 
2003). Extracellular matrix (ECM), composed of collagen, elastin, structural 
glycoproteins, proteoglycans and some minor components, is either overproduced, 
degraded deficiently, or both. The trigger is chronic injury, especially, if there is an 
inflammatory component. Current evidence indicates that HSCs are central 
mediators of fibrogenesis (Friedman, 2004; Friedman, 2008). HSCs are the major 
cellular producer of ECM proteins (mainly collagen types I, III and IV). As already 
mentioned in 3.1.1 in healthy liver, HSCs are mainly in a quiescent state 
containing droplets of vitamin A in their cytoplasm. Quiescent HSCs are involved 
in ECM homeostasis as they express metalloproteinases (MMPs) for ECM 
degradation and inhibitors of metalloproteinases (TIMPs) for ECM maintenance, 
respectively (Atzori et al., 2009). As response to various stimuli during liver injury, 
quiescent HSCs undergo morphological changes associated with a loss of their 
vitamin A reservoir. This activation process is a hallmark of fibrogenesis (Friedman 
and Arthur, 1989). HSCs transform into highly proliferative myofibroblast like cells 
(activated HSCs) which express α smooth muscle actin (αsma), a histological 
marker of activated HSCs in injured liver (Mann and Mann, 2009). Activated HSCs 
migrate to and accumulate at the side of tissue repair. They overproduce ECM 
proteins (mainly collagen type I) and TIMPs (mainly TIMP-1) which in turn block 
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matrix degradation by MMPs. Further, activated HSCs up-regulate an array of 
cytokines (e.g. IL-6), chemokines (e.g. MCP-1), and mitogens (e.g. TGF-β and 
PDGF) which further activate HSCs in an autocrine manner. Moreover, activated 
HSCs are characterized by high resistance to apoptosis. They survive prolonged 
serum deprivation as well as established pro-apoptotic stimuli like e.g. Fas ligand 
(Novo et al., 2006). One key transcription factor in the activation of hepatic stellate 
cells is NFκB. This signaling pathway is mediating apoptosis resistance (Oakley et 
al., 2005; Watson et al., 2008). NFκB also induces proinflammatory gene 
expression such as MCP1 and RANTES (Elsharkawy et al., 2005; Hellerbrand et 
al., 1998; Schwabe et al., 2003).  
3.2.2 Cirrhosis 
Accumulation of ECM in advanced fibrosis deforms hepatic architecture by 
building up fibrous scar and subsequent development of nodules of regenerating 
hepatocytes ascertains cirrhosis. Patients suffering from cirrhosis exhibit disturbed 
hepatic blood flow and hepatocellular dysfunction. The outcome of this is hepatic 
insufficiency and portal hypertension (Gines et al., 2004; Iredale, 2003). Further 
pathological changes can occur such as liquid in the abdominal cavity (ascites) 
and formation and bleeding of esophagal varices, muscle wasting, bleeding from 
the intestines, enlarging of mens’ breasts (gynaecomastia) and so on (Schuppan 
and Afdhal, 2008). Finally, cirrhosis results in loss of liver function 
(decompensated cirrhosis) a condition with high morbidity and mortality (Pinzani et 
al., 2011).  
3.3 Trigger of chronic liver disease 
Initiation of chronic hepatic inflammation, liver damage and ultimately liver failure 
caused by persisting fibrosis can result in complete cirrhosis and loss of liver 
function. Several mechanisms can be the cause for the progression of chronic liver 
disease. Namely chronic alcohol abuse (Gramenzi et al., 2006), 90% of heavy 
drinkers develop fatty liver and about 30% display more severe forms such as 
fibrosis and cirrhosis (Gao and Bataller, 2011). Further, drugs being metabolized 
by the liver can induce liver disease such as acute liver failure (ALF), acute 
hepatic necrosis, chronic hepatitis, triggered by various mechanisms of 
hepatotoxicity, such as cell death resulting from direct binding of the drug to 
cellular proteins, dysregulation of the cytoskeleton or inhibition of mitochondrial 
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function (Navarro and Senior, 2006). Autoimmune related disorders such as 
autoimmune hepatitis (Krawitt, 2006), and cholestatic autoimmune diseases like 
primary biliary cirrhosis and primary sclerosing cholangitis lead to the progression 
of chronic liver disease (Boonstra et al., 2012). Genetic disorders such as 
hereditary hemochromatosis which leads to liver iron overload (van Bokhoven et 
al., 2011), Wilson disease, an autosomal recessive disorder, that leads to an 
accumulation of copper in the liver (Rosencrantz and Schilsky, 2011) and Gilberts 
syndrome which affects billirubin levels (Strassburg, 2008) affect hepatic function 
and induce chronic liver disease. Beyond, viral hepatitis A-E influence liver 
function unequally, thus, leading from acute infection without chronic course (A) to 
fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (C) (Qu and Lemon, 2010). 
Another common cause of chronic liver disease is the induction of non-alcoholic 
fatty liver disease (NAFLD) which will be illustrated in the subsequent chapter.  
3.3.1 Non-alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is a clinico-pathological condition of 
rising importance. It is characterized by hepatic lipid accumulation which starts 
with simple hepatic steatosis and progresses towards hepatocellular injury and 
inflammation (non-alcoholic steatohepatitis [NASH]) in a significant number of 
patients NASH is the most common origin of abnormal liver tests in Western 
societies and its incidence is further increasing worldwide (Bosserhoff and 
Hellerbrand, 2011; Hellerbrand, 2010; Straub and Schirmacher, 2010). The 
pathology of NAFLD was first described in 1980 by Ludwig who obtained steatosis 
and inflammation in livers of patients without alcohol consumption (Ludwig et al., 
1980). NAFLD ranges from simple hepatic steatosis with triglyceride accumulation 
in hepatocytes to Non-alcoholic steatohepatitis (NASH), which is histologically 
verifiable by ballooning hepatocytes and cell death. The prevalence of NAFLD 
correlates with obesity/BMI in adults and children (Bjornsson and Angulo, 2007) 
and advancing age (Frith et al., 2009). Obesity, type 2 diabetes, hypertension or 
dyslipidemia are frequently associated with NAFLD. Therefore, NAFLD is 
considered as the hepatic manifestation of the metabolic syndrome, and sedentary 
lifestyle combined with high caloric intake is the major cause of NAFLD (de Alwis 
and Day, 2008). A two hit model was raised to explain the progression (Day and 
James, 1998). The first hit resembles an imbalance between lipid intake and 
removal and the second hit induces inflammation. But it seems that a third hit 
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needs to be evaluated which explains ongoing fibrosis ultimately leading to 
cirrhosis in some patients. The outcome in patients suffering from simple hepatic 
steatosis is good involving change of lifestyle, food intake and weight loss. 20-30% 
of steatosis patients develop NASH and within 10 years in 10-30% of those 
patients evolve cirrhosis (Argo and Caldwell, 2009; Argo et al., 2009). The NASH 
induced cirrhosis can further be a trigger for the progression of HCC (Baffy et al., 
2012). 
3.3.2 Effects of reactive oxygen species (ROS) on fibrosis 
Clinical and experimental data suggest that oxidative stress mediates the 
progression of fibrosis, and that oxidative stress related molecules may act as 
mediator of molecular and cellular events implicated in liver fibrosis. The 
generation of reactive oxygen species (ROS) plays an important role in producing 
liver damage and initiating hepatic fibrogenesis. Oxidative stress disrupts lipids, 
proteins and DNA, induces necrosis and apoptosis of hepatocytes and amplifies 
the inflammatory response. ROS also stimulate the production of profibrogenic 
mediators from Kupffer cells and circulating inflammatory cells and directly activate 
hepatic stellate cells, resulting in the initiation of fibrosis (Parola and Robino, 2001; 
Pinzani and Rombouts, 2004; Sanchez-Valle et al., 2012).  
3.3.2.1 Effects of ROS formation on methylation 
In addition to causing genetic changes, ROS may lead to epigenetic alterations 
that affect the genome and play a key role in the development of human malignant 
transformation (Campos et al., 2007; Ziech et al., 2011). More specifically, ROS 
production is associated with alterations in DNA methylation patterns (Campos et 
al., 2007; Donkena et al., 2010; Ziech et al., 2010). ROS-induced oxidative stress 
can contribute to gene silencing by mechanisms that involve aberrant 
hypermethylation of tumor suppressor gene promoter regions and thus lead 
towards progression to a malignant phenotype. Our group could show that in HCC 
the methylthioadenosine phosphorylase (MTAP) promoter is hypermethylated 
which results in decreased MTAP expression (Hellerbrand et al., 2006). Exposure 
of HCC cells to ROS induced hypermethylation of the E-cadherin (Lim et al., 2008) 
and catalase promoter (Min et al., 2010). 
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3.4 Characterisation of polyamine metabolism and methionine 
pathways 
3.4.1 Methylthioadenosine phosphorylase (MTAP) 
MTAP catalyzes the phosphorylation of 5'-deoxy-5'-(methylthio)adenosine (MTA) 
(Figure 3.3) which is formed as a by-product of polyamine synthesis to yield 
adenine and methylthioribose-1-phosphate (MTR-1P). MTR-1P is then converted 
in a series of enzymatic reactions to regain methionine (Backlund, Jr. and Smith, 
1981). While adenine is subsequently recycled back into nucleotides through the 
action of phosphoribosyltransferases (Savarese et al., 1981). MTAP activity is 
responsible for essentially all of the free adenine generated in human cells 
(Kamatani and Carson, 1981), indicating that this enzyme performs an important 
function in the purine salvage pathway. Regaining methionine and adenine are 
essential responsibilities of MTAP. Beyond, MTAP is necessary to obtain 
polyamine metabolism to work properly.  
 
Figure 3.3 Metabolic pathways in which MTAP is involved. MTA resulting from polyamine 
pathway is metabolized by MTAP forming adenine necessary for DNA synthesis and 
MTR-1-P to regain methionine. 
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Loss of MTAP has been shown to cause a significant decrease in intracellular 
polyamine levels and alters the ratio of putrescine to total polyamines in vitro 
(Christopher et al., 2002; Subhi et al., 2003). The mechanism involves the 
accumulation of MTAP's substrate, MTA which in higher concentrations acts as a 
potent inhibitor of spermine and spermidine synthase, two key enzymes of the 
polyamine synthetic pathway (Subhi et al., 2003). MTAP activity was first 
characterized in rat ventral prostate in 1969 (Pegg and Williams-Ashman, 1969). 
Biochemical evidence suggests that mammalian MTAP is a trimer made up of 
three identical sub-units of 32 kDa (Della et al., 1990; Della et al., 1996). Each 
subunit in the human enzyme contains 283 amino acid residues. Consistent with 
its central metabolic role MTAP expression is high in normal liver tissue (Kamatani 
et al., 1981; Nobori et al., 1996). MTAP deficiency is common in human and 
murine malignant cell lines (Kamatani et al., 1981; Toohey, 1977). The abnormality 
is not confined to tissue culture cells, but is also present in primary leukemias, 
gliomas, and non-small cell lung cancers (Fitchen et al., 1986; Kamatani et al., 
1981; Nobori et al., 1991; Nobori et al., 1993). In hepatocellular carcinoma (HCC) 
loss or downregulation of MTAP leads to an accumulation of MTA which promotes 
tumorigenicity (Berasain et al., 2004; Kirovski et al., 2011).  
3.4.1.1 MTAP structure 
The human MTAP gene (EC 2.4.2.28) resides on the short arm of chromosome 9, 
in the chromosomal region 9p21, from 21792543 to 22111094 (5' 3'). It consists 
of eight exons and seven introns. Exon 1 encodes 11 amino acids and the 5' 
noncoding region, the sizes of exons 2-7 range from 79 to 240 bp. The last (8th) 
exon encodes the C-terminal 12 amino acids and the 3' noncoding region (Nobori 
et al., 1996). 
3.4.1.2 MTAP expression in vivo 
Regarding the enzymatic responsibilities of MTAP it is obvious that MTAP is 
abundantly expressed in a wide range of healthy cells and tissues (Olopade et al., 
1995). MTAP has been purified from rat liver (Ferro et al., 1978) and exhibits 
highest activity in liver and lung (Garbers, 1978). High hepatic MTAP expression 
can be explained by the key role of the liver in methionine metabolism (Avila et al., 
2004). In various studies concerning malignancies it has been shown that MTAP 
expression is downregulated or even lost. Genomic or epigenetic alterations are 
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the cause of decreased MTAP expression. In leukemia (Hori et al., 1998), 
pancreatic adenocarcinoma (Hustinx et al., 2005; Subhi et al., 2004), 
osteosarcoma (Garcia-Castellano et al., 2002), endometrial cancer (Wong et al., 
1998) and lung cancer (Watanabe et al., 2009) partial or complete deletions of 
MTAP account for lost expression. In contrast, MTAP is overexpressed in human 
colon carcinoma (Bataille et al., 2005). For hepatocellular carcinoma (HCC) 
(Hellerbrand et al., 2006), melanoma (Behrmann et al., 2003) as well as 
lymphoma (Ishii et al., 2005) hypermethylation has been shown to account for 
decreased MTAP expression. MTAP is located in the 9p21 chromosomal region 
(Carrera et al., 1984; Nobori et al., 1996), an area which has been described to 
play a role in various human malignancies such as type 2 diabetes (Cugino et al., 
2012), coronary artery disease (Roberts and Stewart, 2012), melanoma (Cooper 
et al., 2012), leukemia (Ragione and Iolascon, 1997) and HCC (Liew et al., 1999). 
The 9p21 area contains p15-p16-MTAP-IFNa-IFNb (Olopade et al., 1995). P15 
and p16 specifically inhibit cyclin D-associated kinases (Parry et al., 1995; Sandhu 
et al., 1997) and are both considered to be tumor suppressors (Tsihlias et al., 
1999). Savarese and colleges could show co- deletions of MTAP and one or more 
genes in malignant cells (Chen et al., 1996; Zhang et al., 1996). MTAP deficiency 
per se was shown to induce accumulation of MTA in melanoma and HCC which 
promotes tumorigenicity (Kirovski et al., 2011; Stevens et al., 2009). 
3.4.1.3 Effect of MTAP manipulation in vivo and in vitro 
In vivo repression of MTAP enzyme activity with an inhibitor increased MTA levels 
in blood and urine and beyond tumor growth was inhibited in nude mouse models 
(Basu et al., 2011). In vitro contradictory results were obtained. In a MCF-7 breast 
cancer cells line it was shown that reexpression of the MTAP enzyme activity 
inhibits colony formation and suppressed tumor formation in implanted mice. The 
authors consider MTAP to have tumor suppressor activity and suggest that its 
effects may be mediated by altering intracellular polyamine pools (Christopher et 
al., 2002). A study by Subhi supports this idea so they showed that MTAP 
regulates ornithine decarboxylase (ODC) which is the rate limiting enzyme for 
polyamine production (Figure 3.3) (Subhi et al., 2003). For pancreatic carcinoma 
an inverse correlation of MTAP and ODC activity could be shown (Subhi et al., 
2004). Inhibition of MTAP enzyme activity has been shown to induce apoptosis 
(Basu et al., 2011).  
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3.4.1.4 Regulation of MTAP 
As already described in most malignancies loss of MTAP is due to homozygous 
deletions of the MTAP gene. Our group (Hellerbrand et al., 2006) and others 
(Berasain et al., 2004) have shown that in HCC MTAP is downregulated via 
promoter hypermethylation. This mechanism can also be observed for melanoma 
and lymphoma (Behrmann et al., 2003; Ishii et al., 2005). Transcriptional activation 
of the MTAP promoter by binding of CCAAT binding factor to a distal CCAAT motif 
in the MTAP promoter was also described (Kadariya et al., 2005). 
MTAP activity was shown to be regulated by various mechanisms. In liver tissue of 
mice treated with LPS reduced MTAP activity, increased ODC activity and an 
accumulation of MTA was measured whereas no difference in MTAP protein could 
be obtained (Fernandez-Irigoyen et al., 2008). Further, treatment of HCC cells with 
reactive oxygen species (ROS) decreased MTAP activity (Fernandez-Irigoyen et 
al., 2008). Analogues of adenosine such as 5’- Deoxyadenosine can block MTAP 
activity (Fabianowska-Majewska et al., 1994).  
3.4.2 5'-deoxy-5'-(methylthio)adenosine (MTA)- structure and 
abundance 
The substrate of the enzyme MTAP is 5'-deoxy-5'-(methylthio)adenosine (MTA) 
whose occurrence was described about 100 years ago. The molecular structure 
was described in 1924 (Williams-Ashman et al., 1982). The biological importance 
of MTA became apparent in 1952, 1 year before the discovery of its metabolic 
precursor S-adenosylmethionine (AdoMet), in studies on the metabolic 
interrelationship of methionine and 5-thiomethylribose (Williams-Ashman et al., 
1982). MTA is abundant in small amounts in all cell types, including prokaryotes, 
yeast, plants and higher eukaryotes. In mammalian tissues, MTA is mainly 
produced during the biosynthesis of polyamines (Figure 3.4) (Pegg, 1988; 
Williams-Ashman et al., 1982). For many years, this nucleoside has received by 
far much less attention than its precursor AdoMet. However, MTA exhibits a lot of 
different effects in various mammalian cells and tissue.  
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Figure 3.4 5'-deoxy-5'-(methylthio)adenosine (MTA) is a hydrophobic sulfur-containing 
adenine nucleoside in which the hydroxyl group in the 5 position of the ribose is 
substituted by a methylthio moiety. This methylthio moiety is derived from the amino acid 
methionine, while the rest of the molecule comes from ATP. 
 
As already mentioned MTA is mainly produced in polyamine pathway and is 
synthesized in stochiometric amounts to spermidine and spermine. The 
biosynthesis of polyamines starts with the decarboxylation of AdoMet and 
decarboxylated AdoMet serves as substrate for aminopropyltransferases. These 
enzymes transfer the aminopropyl moiety from decarboxylated AdoMet to 
putrescine whereas spermidine is formed and to spermidine which forms 
spermine. MTA is metabolized by MTAP which results in the formation of adenine 
and MTR-1P. This metabolite is finally converted into methionine, and adenine is 
salvaged to ultimately replenish the AMP and ATP pools. Consequently, the two 
metabolites from which AdoMet and MTA are formed, namely methionine and 
ATP, are thus recovered (Figure 3.3) (Avila et al., 2004; Williams-Ashman et al., 
1982). The conversion of MTR-1P into methionine involves a complex set of 
oxidations via the intermediate 4-methylthio-2-oxobutanoic acid (MTOB). This 
efficient cycle sustains the high rate of polyamine synthesis that occurs during 
cellular proliferation and provides methionine for AdoMet and protein synthesis. In 
addition, the removal of accumulating MTA by MTAP is necessary for the cell to 
carry out polyamine metabolism, since MTA is a strong inhibitor of spermine 
synthase, and to a lesser extent of spermidine synthase and of ODC (Pascale et 
al., 2002; Pegg and Williams-Ashman, 1969). The inhibition of ODC by MTA can 
be mediated in part by its metabolite MTOB, as has been recently demonstrated in 
yeast and human tumor cells (Subhi et al., 2003). 
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3.4.2.1 Effects of MTA in vivo and in vitro 
Analyzing the literature there are contradictory results regarding the effects of 
MTA. But it is evident that MTA performs fundamental cellular functions and thus 
influences metabolism significantly. In vivo MTA was shown to rescue killing effect 
of LPS injection (Hevia et al., 2004), to inhibit tumor growth in a melanoma 
xenograft mouse model (Andreu-Perez et al., 2010) and to ameliorate malignant 
transformation of Mdr2-/- mice (Latasa et al., 2010). In an AOM/DSS experimental 
inflammation induced colon cancer model in mice MTA treatment reduced 
proinflammatory gene expression and proliferation and induced apoptosis (Li et 
al., 2012). For rats MTA donation slowered disease progression of experimental 
autoimmune encephalomyelitis (Moreno et al., 2010) and in a CCl4 rat model MTA 
decreased proinflammatory and profibrogenic gene expression (Simile et al., 
2001).  
In vitro focussing on liver metabolism different results were obtained dependent on 
MTA concentrations used in the experiments. For hepatocellular carcinoma (HCC) 
MTA concentrations up to 5µM increased proliferative capacity, tumorigenicity as 
well as proinflammatory gene expression (Kirovski et al., 2011). MTA 
concentrations from 10 up to 500µM rescued rat hepatocytes from okadaic acid 
induced apoptosis while same doses of MTA promoted induction of apoptosis in 
hepatoma cell lines (Ansorena et al., 2002). The activation of hepatic stellate cells 
(HSCs) is considered to be the key event of hepatic fibrosis (Bataller and Brenner, 
2005; Friedman, 2008) and MTA was shown to inhibit HSC activation at doses of 
25-500µM (Simile et al., 2001). 200-500µM MTA blocked profibrogenic gene 
expression as well as proliferation of activating HSCs (Latasa et al., 2010). 
Further, decreased rather than increased invasiveness induced by MTA were 
suggested in a study examining two rat ascites hepatoma cell lines, possibly due 
to alterations in the phospholipid composition and fluidity of the tumor cell 
membranes (Kido et al., 1991). In cultured melanoma cell lines, exogenous 
addition of 50-100µM MTA caused up-regulation of tumor-promoting genes and 
enhanced invasiveness and vasculogenic mimicry while no similar gene up-
regulation was observed in normal melanocytes (Stevens et al., 2009). Several 
pathways are affected by MTA. It is able to inhibit growth-factor induced protein 
tyrosine phosphorylation and to increase intracellular cAMP levels through the 
inhibition of cAMP phosphodiesterase (Maher, 1993; Riscoe et al., 1984). MTA 
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concentrations used in these experiments were much higher than physiologically 
occurring. NFκB was shown to be induced or inhibited depending on cells and 
concentrations (Hevia et al., 2004; Kirovski et al., 2011; Veal et al., 2004). One of 
the best-characterized actions of MTA is the inhibition of protein methylation 
(Williams-Ashman et al., 1982). This post-translational modification may occur at 
arginine residues or at the carboxyl terminus of proteins, and is thought to 
modulate cellular signaling and gene expression (Law et al., 1992; Lee and Cho, 
1998; Mowen et al., 2001). To further complicate the understanding of the cellular 
responses to MTA, some of the effects of this molecule on the regulation of gene 
expression have been attributed to its ability to replenish the cellular AdoMet pool 
through the methionine salvage pathway (Martinez-Chantar et al., 2003). 
3.4.3 AdoMet: MAT 
 
Figure 3.5 Methionine metabolism: Methionine adenosyltransferase (MAT) catalyzes the 
conversion of methionine and ATP into AdoMet (Lu and Mato, 2012).  
 
S-Adenosyl-L-Methionine (AdoMet, SAM) was discovered 60 years ago and 
gained attention as major biological methyl donor but it has also principal roles in 
diverse cellular processes including growth and death (Lu and Mato, 2012). 
Methionine adenosyltransferase (MAT) is the enzyme that catalyzes the 
biosynthesis of AdoMet from ATP and methionine. MAT is one of the genes that is 
essential to sustain life (Glass et al., 2006). In mammals, all cells and tissues that 
have been studied express MAT, its activity being highest in the liver (Finkelstein, 
1990). Consequently, individuals with hepatic MAT activity deficiency are 
characterized by isolated persistent hypermethioninemia (Ubagai et al., 1995). 
Mammals express two genes, MAT1A and MAT2A, which encode for two 
homologous MAT catalytic subunits, α1 and α2 (Kotb et al., 1997). MAT1A is 
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mostly expressed in normal liver, and the α1 subunit organizes into two MAT 
isoenzymes, MAT III (dimer) and MAT I (tetramer) (Kotb et al., 1997). MAT2A is 
widely distributed, and it encodes for a catalytic subunit (α2) found in the MAT 
isoenzyme MAT II that also exists in polymeric forms that vary from tissue to tissue 
(Horikawa et al., 1993; Kotb and Kredich, 1985). Fetal liver expresses MAT2A and 
MAT2B but not MAT1A (Gil et al., 1996; Yang et al., 2008). MAT1A expression 
increases a few days after birth and progressively takes over so that the adult liver 
(mostly hepatocytes) expresses mainly MAT1A, very little MAT2A, or MAT2B (Gil 
et al., 1996; Yang et al., 2008). Hepatic MAT1A gene expression is downregulated 
in HCC (Cai et al., 1996), during dedifferentiation (Lu and Mato, 2008; Vazquez-
Chantada et al., 2010), in most cirrhotic patients (Avila et al., 2000), and in 
patients with alcoholic hepatitis (Lee et al., 2004). The mechanisms of MAT1A 
downregulation occur both at transcriptional and posttranscriptional levels. The 
Mat1a KO mouse model has provided much insight into the consequences of 
chronic hepatic AdoMet deficiency and altered signaling pathways that may lead to 
malignant degeneration. Mat1a KO mice appear normal at a young age but are 
more susceptible to steatosis induced by a choline-deficient diet and liver injury 
induced by CCl4 , and they develop NASH and HCC spontaneously on a normal 
diet by 8 and 18 months, respectively (Lu et al., 2001; Martinez-Chantar et al., 
2002). Mat1a KO mice have increased hepatic oxidative stress (Martinez-Chantar 
et al., 2002), show genomic instability (Tomasi et al., 2009), dysregulated signaling 
pathways (Chen et al., 2004; Tomasi et al., 2010; Varela-Rey et al., 2011; 
Vazquez-Chantada et al., 2009), have abnormal lipid homeostasis (Lu et al., 2001; 
Martinez-Chantar et al., 2002) and exhibit cancer cell expansion (Rountree et al., 
2008).  
Mouse models to study the effects of excess AdoMet resulted in spontaneous 
development of NASH and HCC (Liao et al., 2009; Martinez-Chantar et al., 2008). 
AdoMet treatment is well established to ameliorate liver injury in multiple animal 
models, including galactosamine, acetaminophen, alcohol, thioacetamide, 
endotoxemia, CCl4 , bile duct ligation (BDL), NASH, and ischemia-reperfusion 
(Cave et al., 2007; Cederbaum, 2010; Ko et al., 2008; Lu and Mato, 2012; Mato et 
al., 1997; Yang et al., 2010; Yang et al., 2009). AdoMet not only protected against 
acute injury, it also reduced fibrosis in multiple experimental models (Cederbaum, 
2010; Yang et al., 2010). 
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3.5 Aim of the study  
Previous in vitro and in vivo studies in our group (Hellerbrand et al., 2006; Kirovski 
et al., 2011) suggested a functional role of MTAP in HCC progression. We wanted 
to expand our study on chronic liver disease which can be considered as a 
precancerous condition. Our goals were to investigate whether MTAP functionally 
affects hepatic stellate cells which can be called the cellular key players of hepatic 
fibrosis (Bataller and Brenner, 2005; Friedman, 2008). We further wanted to 
ascertain whether there is a correlation between MTAP expression an MTA levels 
in vivo as we have already shown in HCC (Kirovski et al., 2011). In vitro alteration 
of MTA levels was shown to have different effects depending on used MTA 
concentration (Kirovski et al., 2011; Latasa et al., 2010). We wanted to asses 
effects of physiologic relevant doses on hepatic stellate cells and the functional 
effects of those doses. There are not much regulatory mechanisms known 
affecting MTAP expression. It is known that MTAP activity is regulated by reactive 
oxygen species in HCC cells (Fernandez-Irigoyen et al., 2008) and the generation 
of ROS plays a pivotal role in the pathogenesis of chronic liver disease (Parola 
and Robino, 2001; Pinzani and Rombouts, 2004; Sanchez-Valle et al., 2012) so 
we wanted to know whether the generation of ROS has an impact on the 
regulation of MTAP expression. Induction of methylation is associated with 
cirrhosis (Ziech et al., 2011) and also it was described that ROS induce 
methylation reactions (Lim et al., 2008; Min et al., 2010). So, the aim was to 
assess whether methylation in combination with the induction of reactive oxygen 
species has an impact on MTAP expression. 
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4 Materials and Methods 
4.1 Chemicals and Reagents 
5- Azacytidine (Aza) Sigma-Aldrich, Deisenhofen, Germany 
Acrylamid Carl Roth, Karlsruhe, Germany 
Adenosine periodate oxidized (AdOx) Sigma-Aldrich, Deisenhofen, Germany 
Agar Difco Laboratories, Augsburg 
Agarose SeaKem® LE Biozym, Hess/Oldendorf, Germany 
Ampicillin Sigma-Aldrich, Deisenhofen, Germany 
APS Sigma-Aldrich, Deisenhofen, Germany 
Bovine serum albumine (BSA) Biozym, Hess/Oldendorf, Germany 
Ciprobay Bayer, Leverkusen, Germany 
Ciprofloxacin Fresenius Kbi, Bad Homburg, Germany 
Collagenase type IV Sigma-Aldrich, Hamburg, Germany  
DEPC Carl Roth GmbH, Karlsruhe, Germany 
Diflucan Pfizer, Karlsruhe, Germany 
DMEM medium PAA Laboratories, Cölbe, Germany 
DMSO Sigma-Aldrich, Deisenhofen, Germany 
Ethanol J.T. Baker, Deventer, The Netherlands 
Fatty Acid free BSA Sigma-Aldrich, Deisenhofen, Germany 
FCS (fetal calf serum) PAN-Biotech, Aidenbach, Germany 
FITC Annexin V PromoKine, Heidelberg, Germany 
Fluconazol B. Braun, Melsungen, Germany 
Geneticin Gibco/Invitrogen 
Methanol Merck, Darmstadt, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
5'-deoxy-5'-(methylthio)adenosine 
(MTA) 
Sigma-Aldrich, Deisenhofen, Germany 
Oleic acid Sigma-Aldrich, Deisenhofen, Germany 
PBS PAA Laboratories, Cölbe, Germany 
Penicillin Invitrogen, Karlsruhe, Germany 
Ponceau S Sigma-Aldrich, Deisenhofen, Germany 
Propidium iodie Sigma-Aldrich, Deisenhofen, Germany 
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Roti Safe Carl Roth, Karlsruhe, Germany 
Staurosporine (STS) Enzo Life Sciences, Lörrach, Germany 
Streptomycin Invitrogen, Karlsruhe, Germany 
TEMED Sigma-Aldrich, Deisenhofen, Germany 
Trypan blue Sigma-Aldrich, Deisenhofen, Germany 
Trypsin/EDTA PAA Laboratories, Cölbe, Germany 
Tween 20® Sigma-Aldrich, Deisenhofen, Germany 
β-Mercaptoethanol Sigma-Aldrich, Deisenhofen, Germany 
 
4.2 Laboratory expendables 
CryoTube vials Nunc, Roskilde, Denmark 
Pipet tips 
(10, 20, 100 und 1000µl) 
Eppendorf, Hamburg, Germany 
Falcon tubes (15 and 50ml) Corning, New York, USA 
Glassware (various) Schott, Mainz, Germany 
Multiwell plates (various sizes) Corning, New York, USA 
Pipettes (stripettes®) 
(5, 10, 25, 50ml) 
Corning, New York, USA 
Reaction vessels (1.5 and 2ml) Eppendorf, Hamburg, Germany 
Strip tubes (0.2ml) Peqlab, Erlangen , Germany 
Cell culture flasks T25, T75, T175 Corning, New York, USA 
Neubauer hemocytometer Marienfeld GmbH, Lauda- Königshofen, 
Germany 
Scalpels (no.11) Pfm, Cologne, Germany 
 
4.3 Laboratory instruments 
Heating block: 
Thermomixer comfort Eppendorf, Hamburg, Germany 
PCR-cycler: 
GeneAmp® PCR System 9700 Applied Biosystems, Foster City, USA 
Q-PCR- cycler 
LightCycler® 480 System 
Roche Applied Science, Mannheim, 
Germany 
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Pipettes: 
Eppendorf Research  
(1000, 200, 100, 20, 10, 2µl) Eppendorf, Hamburg, Germany 
Pipette controllers: 
Accu-jet® Brand, Wertheim, Germany 
Shaking devices: 
KS 260 Basic Orbital Shaker IKA® Werke, Staufen, Germany 
Power Supplies: 
Consort E145 
Power Supply-EPS 301 
 
Peqlab, Erlangen, Germany 
Amersham Biosciences, Munich, 
Germany 
Spectrophotometer: 
EMax® Microplate Reader 
SPECTRAFluor Plus 
 
MWG Biotech, Ebersberg, Germany 
Tecan, Männedorf, Switzerland 
Scale: 
MC1 Laboratory LC 620 D Sartorius, Göttingen, Germany 
Water bath: 
Haake W13/C10 
 
Thermo Fisher Scientific, Karlsruhe, 
Germany 
Centrifuges: 
Biofuge fresco 
Megafuge 1.0 R 
 
Heraeus, Hanau, Germany 
Heraeus, Hanau, Germany 
Microscope: 
Olympus CKX41 with  
ALTRA20 soft imaging system 
Zeiss Axioskop2 mot plus microscope 
 
Olympus Hamburg, Germany 
 
Zeiss, Göttingen, Germany 
Laminar flow: 
Biosafety Cabinet 
Hera Safe, Heraeus, Osterode, 
Germany 
Cell incubator: 
Binder series CB 
Binder, Tuttlingen, Germany 
UV/VIS spectrophotometer: 
NanoDrop® ND-1000 
Peqlab, Erlangen, Germany 
XCELLigence system: 
Real- Time Cell Analyzer (RTCA) 
Roche Applied Science, Mannheim, 
Germany 
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Cell freezing machine: 
Nicool LM 10 freezing machine 
Air Liquide, Düsseldorf, Germany 
 
4.4 Buffers 
PBS buffer 140mM NaCl  
 10mM KCl  
 6.4mM Na2HPO4  
 2mM KH2PO4 pH 7.4 
    
TE buffer 10mM Tris/HCl  
 1mM EDTA pH 8.0 
TBS(T) 20mM  Tris pH 7.4 
 150mM NaCl  
 (0.1% Tween 20®)   
 
4.5 Plasmids 
MTAP  By courtesy of Prof. Bosserhoff 
(Institute of Pathology, University 
Hospital Regensburg) 
pcDNA3.1 Invitrogen, Karlsruhe, Germany 
pGL3 Promega, Mannheim, Germany 
pRL-TK Promega, Mannheim, Germany 
NFκB luc Promega, Mannheim, Germany 
 
4.6 Working with bacteria 
4.6.1 Bacterial strains  
Top10 Invitrogen, Karlsruhe, Germany 
 
4.6.2 Liquid media and agar plates 
LB medium 10 g/L peptone 
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 5 g/L yeast extract 
 10 g/L NaCl 
 Suspended in H2O and autoclaved  
For plates + 15 g/L  Agar 
For selection + 100 µg/ml Ampicillin 
 
4.6.3 Bacterial culture 
E. coli strains were cultivated on solid LB-agar as well as in liquid medium. 
Ampicillin was added to LB medium for selection of insert-containing clones after 
transformation. Bacteria were spread out on agar plates using a Drigalski spatula 
and incubated overnight at 37°C. Liquid cultures were inoculated by a single 
bacterial colony with a sterile pipette tip and grown overnight at 37°C on a shaking 
device (250rpm). 
4.6.4 Transformation 
Top 10 cells were thawed on ice and 100ng plasmid DNA were added. After 30min 
incubation on ice cells were heat shocked at 42°C for 45s and immediately cooled 
on ice to enable plasmid DNA entering the cell. Thereafter, 500µl pre-warmed 
SOC medium was added and the cell suspension was incubated for 1h at 37°C 
with shaking. Then 50-150µl of the transformation mix were plated and incubated 
over night at 37°C on LB-agar containing the antibiotic necessary for selection of 
transformed cells.  
4.6.5 Isolation of plasmid DNA (mini and midi preparation) 
For mini preparation of plasmid DNA a single E.coli colony was picked and 
cultured with 3ml LB-selection medium at 37°C over night (250rpm).  
To obtain greater amounts of plasmid DNA 50µl of this preculture was added to 
50 ml LB-selection medium and incubated again at 37°C over night (250rpm). 
Then plasmids were isolated using HiSpeedTM Plasmid Midi Kit (Qiagen, Hilden, 
Germany) following the supplier’s instruction. Plasmid DNA was eluated with 
500 µl sterile H2Odest. and stored at -20°C. 
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4.7 Cell culture 
4.7.1 Cell culture medium 
DMEM(high 
glucose/10%FCS) 4.5 g/l Glucose 
 300 µg/ml L-Glutamine 
 supplemented with:  
 10% (v/v) FCS 
 400 U/ml Penicillin 
 50 µg/ml Streptomycin 
HSC medium DMEM (high glucose/10% FCS) 
 supplemented with:  
 10 µg/ml Fluconazol 
 4 µg/ml Ciprofloxacin 
Freezing medium 5 Vol 
DMEM (high glucose/10% 
FCS) 
 3 Vol FCS 
 2 Vol DMSO 
4.7.2 Cultivation of cell lines 
Cell culture work was always performed within a laminar flow biosafety cabinet 
(Hera Safe, Heraeus, Osterode, Germany). Cells were cultivated in a Binder series 
CB incubator (Binder, Tuttlingen, Germany) in 10% CO2 atmosphere at 37°C. 
DMEM medium containing 4.5 g/l glucose and 300 µg/ml L-glutamine 
supplemented with 10% (v/v) FCS, 400 U/l penicillin and 50 µg/ml streptomycin 
was used as cell culture medium. For passaging adherent cells were washed with 
PBS and detached with trypsin (0.05%)/EDTA (0.02%) (PAA Laboratories, Cölbe, 
Germany) at 37°C. Trypsination was stopped adding DMEM containing 10% FCS. 
Subsequently, cells were centrifuged at 500g for 5min and the obtained cell pellet 
was resuspended in fresh culture medium and distributed to new cell culture flasks 
achieving a cell density thinning factor of 5 to 10. Medium was changed every 
second day. Cell growth and morphology were controlled and documented with a 
microscope (Olympus CKX41 with ALTRA20 Soft Imaging System, Olympus, 
Hamburg, Germany). Cell culture waste was autoclaved before disposal with a 
Sanoclav autoclave (Wolf, Geislingen, Germany).  
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4.7.3 Cell line of activated murine hepatic stellate cells 
Activated murine hepatic stellate cells have immortalized spontaneously.  
4.7.4 Isolation of primary human hepatocytes 
Primary human hepatocytes (PHH) were isolated in cooperation with the Center of 
Liver Cell Research (Department of Paediatrics and Juvenile Medicine, University 
of Regensburg, Germany) from human liver resections using a modified two-step 
EGTA/collagenase perfusion procedure (Hellerbrand et. al., 2008; Hellerbrand et 
al., 2007; Pahernik et al., 1996; Ryan et al., 1993; Weiss et al., 2002). 
Experimental procedures were performed according to guidelines of the charitable 
state controlled foundation HTCR, with the informed patient’s consent. For cell 
isolation only tissue which has been classified as not pathological after 
macroscopical and microscopical investigation was used. All used liver resections 
have been negatively tested for HBV, HCV and HIV infection. Viability of the 
isolated hepatocytes was determined by trypan blue exclusion, and cells with 
viability greater than 85% were used for further tests. 
4.7.5 Isolation of hepatic stellate cells 
Human hepatic stellate cells (HSCs) were isolated in cooperation with the Center 
of Liver Cell Research (Department of Paediatrics and Juvenile Medicine, 
University of Regensburg, Germany). After perfusion and separation of 
hepatocytes by an initial centrifugation step at 50g (5min, 4°C) the supernatant 
containing the non-parenchymal cells was centrifuged at 700g for 7min (4°C). The 
obtained cell pellet was resuspended in HSC medium and cells were seeded into 
T75 flasks. Within the first week, the medium was replaced daily, from the second 
week on medium change took place every 2-3 days. Under these conditions only 
HSCs proliferate. Liver sinusoidal endothelial cells (LSEC) die within the first 24h. 
By cultivation on uncoated plastic HSCs activate within the first 2 weeks and 
transdifferentiate to myofibroblast-like cells. Liver disease mediated HSC 
activation can be simulated in vitro that way. After 2 weeks the cell culture was 
split 1:3 by incubating the cells with Trypsin (0.05%)/EDTA (0.02%) solution. 
Thereby, only HSCs detach whereas Kupffer cells remain adherent to the plastic 
surface. Therefore, after the first passage only activated HSCs remain in the cell 
culture which was confirmed by previously done analysis (Mühlbauer et al. 2006). 
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Further, isolation of primary murine HSCs was performed on a regular basis within 
our group from 8-12 weeks old female BALB/c mice (Charles River Labortatories, 
Sulzfled, Germany) according to procedures described previously (Hellerbrand et 
al., 1996). 
4.7.6 Determination of cell number and viability 
Cell number and viability was determined by trypan blue exclusion test. The cell 
suspension was diluted 1:2 with trypan blue solution (Sigma, Deisenhofen, 
Germany) and applied on a Neubauer hemocytometer (Marienfeld GmbH, Lauda-
Königshofen, Germany). Cell with impaired cell membrane integrity are stained 
blue, and therefore, can be clearly distinguished from intact cells which appear 
white under microscopic inspection. The cell number could be calculated after 
counting cells in all four quadrants of the hemocytometer, each containing sixteen 
smaller squares, with the following equation: 
 
Cell number/ml = Z x DF x 104 ÷ 4 
Z: counted cell number 
DF: dilution factor (in the described procedure the factor is 2) 
 
The ratio of viable cells could be determined by setting the number of unstained 
cells in relation to the total cell number (blue and unstained cells). 
4.7.7 Freezing cells for storage 
To freeze cells for storage, cells were trypsinized, centrifuged and resuspended in 
5ml DMEM. Cells were counted, and 1 x 106 cells were pipetted in cryotube vials 
(Nunc, Roskilde, Denmark) and centrifuged again. The supernatant was discarded 
and the obtained cell pellet was resuspended in 1ml of freezing medium. To gently 
freeze the cell suspension the temperature was lowered stepwise using a Nicool 
LM freezing machine (Air Liquide, Düsseldorf, Germany) following the listed 
program: 
 Level 4:  30min 
 Level 8:  30min 
 Level 10:  30min 
Thereafter, the cryotube vials containing the frozen cell suspension were 
transferred to a liquid nitrogen storage tank. 
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Thawing of the frozen cell stocks was done quickly with a water bath adjusted to 
37°C. The defrosted cell suspension was transferred into 8ml of warm DMEM and 
centrifuged at 300g for 5minutes. The obtained cell pellet was resuspended in 
10ml of warm DMEM and pipetted into a T25 cell culture flask. 
4.7.8 Transient siRNA transfection 
siRNA and HiPerFect Transfection Reagent® were purchased from Qiagen 
(Hilden, Germany). 
name target sequence 
MTAP siRNA1 CCCGGCGATATTGTCATTATT 
MTAP siRNA2 AGGCTGGAATTTGTTACGCAA 
All stars negative control siRNA not disclosed 
Transfection of cells was performed according to the manufacturer’s fast-forward 
siRNA transfection protocol.  
Shortly before transfection, 2 x 105 cells per well were seeded on a 6 well plate in 
2,300µl DMEM culture medium containing 10% FCS. 150ng siRNA per well was 
diluted in 100µl DMEM without FCS and 12µl of HiPerFect Transfection Reagent 
was added to the diluted siRNA and mixed. The samples were incubated for 
10min at room temperature to allow the formation of transfection complexes which 
were then added drop-wise onto the cells. After 24h cell medium was changed and 
the cells were grown for another 24- 72h (according to individual experiment set-
up). Successful gene silencing was documented on the mRNA and protein levels 
by quantitative RT-PCR and Western blotting.  
4.7.9 Transient plasmid transfection 
Lipofectamine method with LipofectamineTM and PLUSTM reagent (Invitrogen, 
Karlsruhe, Germany) was used to transfect cells with plasmid DNA. 
For transfection 2x105 cells per well were seeded on a 6-well plate. After 3h 
medium was changed and cells are cultivated in DMEM without FCS over night. 
On the next day medium was again changed to DMEM containing 10% FCS (1ml 
per well) and after 3h cells transfection mix was added to the cells. Transfection 
mix was prepared according the manufacturer’s instructions containing 0.5µg 
plasmid DNA per well. Cell medium was changed after incubation over night. 
Materials and Methods  27 
4.7.10 Luciferase reporter gene assay 
Regulatory DNA sequences can be examined by using reporter gene analysis. To 
determine the activity of a promoter, the corresponding DNA fragment containing 
the promoter region, is cloned into the reporter plasmid pGL3 basic prior to the 
firefly luciferase gene. Expression of the reporter gene is then proportional to the 
activation potential of the cloned DNA fragment. By addition of a substrate 
(luciferin) for the luciferase enzyme chemiluminescence is achieved which can be 
measured in a luminometer.  
Considering different transfection efficiencies in individual experimental assays, 
cells were cotransfected with an additional vector containing the luciferase gene 
from Renilla reniformis (pRL-TK). Chemiluminescence of Renilla luciferase was 
also measured in the luminometer and used for the normalization of the values 
depending on the transfection efficiency. Dual-Luciferase® Reporter Assay 
System (Promega, Mannheim, Germany) was used to perform luciferase assays.  
2 x 105 cells per well were seeded on a 6-well plate and transfected with 0.5µg 
NFκB or AP-1 reporter construct or empty control plasmid and pRL-TK using 
lipofectamine (see 3.7.11). After 24h medium is removed and cells are rinsed 
twice with water. Subsequently, 300µl lysis buffer are added per well and cells 
were gently shaked for 20min at room temperature. Then, 50µl of each approach 
were measured in the luminometer using the provided chemicals in the kit. 
4.8 Isolation and analysis of RNA 
4.8.1 RNA isolation and determination of RNA concentration 
RNA isolation was performed with the RNeasy® mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The principle of RNA 
isolation is based on the absorption of RNA to hydrophilic silicon-gel membranes 
in presence of suitable buffer systems. Biological samples were first lysed and 
homogenized in the presence of a highly denaturing guanidine isothiocyanate 
containing buffer, which immediately inactivates RNases to ensure isolation of 
intact RNA. To homogenize tissue samples a MICCRA D1 homogenizer (ART 
Prozess- & Labortechnik, Müllheim, Germany) was used. 
After lysis, ethanol has been added to provide ideal conditions for the binding of 
RNA to the silica-gel membranes. Contaminants have been washed away with 
suitable buffers before RNA was eluted in water and stored at -80°C. The 
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concentration of RNA was measured with the NanoDrop® ND-1000 UV/VIS 
spectrophotometer (Peqlab, Erlangen, Germany). 
4.8.2 Reverse transcription of RNA to cDNA 
Transcription of RNA to complementary DNA (cDNA) was conducted with the 
Reverse Transcription System Kit (Promega, Mannheim, Germany) which uses 
avian myeloblastosis virus reverse transcriptase (AMV-RT). The working solution 
was pipetted with contamination-free aerosol filter pipet tips after the following 
pipetting scheme: 
 0.5µg   RNA 
 4µl   MgCl2 (25mM) 
 2µl  10x reverse transcription buffer 
 2µl  dNTP mix (10mM) 
 1µl  random primer 
 0.5µl  RNasin ribonuclease inhibitor 
 0.6µl  AMV RT 
 ad 25µl H2Odest. 
For reverse transcription samples were incubated in a GeneAmp® PCR cycler 
(Applied Biosystems, Foster City, USA) for 30min at 42°C. For denaturation of the 
AMV RT the temperature was raised to 99°C for 5min. After cooling down to 4°C 
the obtained cDNA was diluted with 75µl H2Odest. and used immediately or stored 
at -20°C.  
4.8.3 Quantitative real time polymerase chain reaction 
To quantify the expression of specific mRNA, quantitative real time polymerase 
chain reaction (qRT-PCR) was performed with the LightCycler® 480 System 
(Roche Diagnosics, Mannheim, Germany). The qRT-PCR is principally based on a 
conventional polymerase chain reaction (PCR), but offers the additional possibility 
of quantification, which is accomplished by fluorescence measurements at the end 
and/or during a PCR cycle. As fluorescent reagent SYBR® Green (SensiFAST™ 
SYBR No-ROX Kit, Bioline, Luckenwalde, Germany) was used. SYBR® Green 
intercalates with double-stranded DNA whereby the fluorescence emission rises 
significantly. Therefore, the fluorescence signal increases proportionally with the 
amount of PCR products. To quantify the expression of a specific gene of interest, 
the results were normalized to housekeeper 18S mRNA. The results were 
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evaluated with the LightCycler® 480 software release 1.5.0 SP4 following the 
manufacturer’s instructions. qRT-PCR was performed according following 
protocol: 
 2.5µl  H2Odest. 
 
0.25µl  forward primer (20µM) 
 0.25µl  reverse primer (20µM) 
 5µl   SYBR® Green 
Following standard scheme was used and adapted to particular primer melting 
point temperature: 
 Initial denaturation:     95°C 2min 
 Two step PCR (45 cycles):  95°C 5s 
       60°C 18s 
 Analysis of melting curve:   95°C  5s 
       65°C 1min 
       97°C 0sec 
For validation, after qRT-PCR, PCR product was mixed with loading buffer 
(Peqlab, Erlangen, Germany) and loaded on a agarose gel with ROTI safe 
(50 µg/100ml gel) to determine the PCR product length. Each experimental 
condition was performed in triplicates and experiments were repeated at least 
three times. 
Table 1 Sets of used forward and reverse primers for qRT-PCR, species: mouse or human 
name forward primer reverse primer 
18s 5’ AAACGGCTACCACATCCAAG 5’ CCTCCAATGGATCCTCGTTA 
human α-sma 5’ CGTGGCTATTCCTTCGTTAC 5’ TGCCAGCAGACTCCATCC 
human BAX 5’ GGCCCACCAGCTCTGAGCAGA 5’ GCCACGTGGGCGTCCCAAAGT 
human BclXl 5’ GCGGATTTGAATCTCTTTCTC 5’ CACTAAACTGACTCCAGCTG 
human Coll I 5’ CGGCTCCTGCTCCTCTT 5’ GGGGCAGTTCTTGGTCTC 
human MTAP 5’ GCGAACATCTGGGCTTTG 5’ GCACCGGAGTCCTAGCTTC 
human survivin 5’ AGTGAGGGAGGAAGAAGGCA 5’ ATTCACTGTGGAAGGCTCTGC 
human XIAP QIAGEN QuantiTect Primer Assay 
murine α-sma QIAGEN QuantiTect Primer Assay 
murine BAX 5’ TGCAGAGGATGATTGCTGAC 5’ GATCAGCTCGGGCACTTTAG 
murine BclXl QIAGEN QuantiTect Primer Assay 
murine CCl2 5’ TGGGCCTGCTGTTCACA 5’ TCCGATCCAGGTTTTTAATGTA 
murine CCl5 QIAGEN QuantiTect Primer Assay 
murine Coll I 5’ CGG GCA GGA CTT GGG TA 5’ CGG AAT CTG AAT GGT CTG ACT 
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murine HMOX 5’ CACGCATATACCCGCTACCT 5’ CCAGAGTGTTCATTCGAGCA 
murine MTAP 5’ CGGTGAAGATTGGAATAATTGG 5’ ATGTTTGCCTGGTAGTTGAC 
murine 
p47phox 
QIAGEN QuantiTect Primer Assay 
murine survivin 5’ GTACCTCAAGAACTACCGCA 5’ TCTATGCTCCTCTATCGGGT 
murine XIAP QIAGEN QuantiTect Primer Assay 
 
Primers were synthesized by SIGMA Genosys (Hamburg, Germany) or purchased 
as QuantiTect Primer Assays from Qiagen (Hilden, Germany). The lyophilized 
primers were solved in H2Odest. or TE buffer (QuantiTect Primer Assays), 
respectively, and stored at -20°C. 
4.9 Protein analysis 
4.9.1 Preparation of protein extracts 
To extract whole cell protein from cell lines, cultivated in 6-well plates the cell 
culture medium was discarded and cells were washed once with PBS, then 
scraped off with a cell scraper (Corning, New York, USA) and taken up into 350µl 
cell lysis buffer (Cell Signaling Technology, Boston, USA) supplemented with 1mM 
PMSF and a protease inhibitor cocktail (cOmplete Mini Protease Inhibitor Cocktail 
Tablets from Roche Diagnostics, Mannheim, Germany). Liver tissue extracts were 
obtained by homogenization of snap-frozen liver tissue in cell lysis buffer 
containing 1mM PMSF and protease inhibitors using a MICCRA D1 homogenizer 
(ART Prozess- & Labortechnik, Müllheim, Germany). Subsequently, probes were 
treated with an ultrasonoscope (Sonoplus hp 70, Bandelin electronics, Berlin, 
Germany) 5 x 3s at an intensity of 70% for cell lysis. Subsequently, the solved 
proteins were separated from the non-soluble cell components by centrifugation at 
20.000g (15min, 4°C). The protein solution was transferred into new reaction tubes 
and stored at -20°C.  
4.9.2 Determination of protein concentration 
To determine the protein concentrations of protein solutions the BCATM Protein 
Assay Kit (Pierce, Rockford, USA) was used. The assay combines the reduction of 
Cu2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of the cuprous cation Cu1+ by bicinchoninic acid 
(BCA). The first step is the chelation of copper with protein in an alkaline 
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environment to form a blue-colored complex. In this reaction, known as biuret 
reaction, peptides containing three or more amino acid residues form a colored 
chelate complex with cupric ions in an alkaline environment. One cupric ion forms 
a colored coordination complex with four to six nearby peptides bound. In the 
second step of the color development reaction, BCA, a highly sensitive and 
selective colorimetric detection reagent reacts with the cuprous cation Cu1+ that 
was formed in step 1. The purple-colored reaction product is formed by the 
chelation of two molecules of BCA with one cuprous ion. The BCA/copper complex 
is water-soluble and exhibits a strong linear absorbance at 562 nm with increasing 
protein concentrations. 200µl of alkaline BCA/copper(II) solution (50 parts of 
solution A mixed with 1 part of solution B) was added to 2µl of protein solution 
using a 96-well plate and were incubated for 15min at 37°C. Thereafter the purple 
color was measured at 562 nm with a spectrophotometer (EMax® Microplate 
Reader, MWG Biotech, Ebersberg, Germany). The optical absorbance values 
could be translated into specific protein concentrations by parallel quantification of 
a BSA standard. 
4.9.3 SDS polyacrylamid gel electrophoresis (SDS-PAGE) 
Used buffers: 
Laemmli buffer  62.5mM Tris/HCl; pH6.8 
    2% (w/v) SDS 
    10% (v/v) Glycerine 
    5% (v/v) β-Mercaptoethanol 
 
Running buffer  25mM  Tris/HCl; pH8.5 
    200mM Glycine  
    0.1% (w/v) SDS 
 
10% Resolving gel  7.9ml  H2Odest.  
    5.0ml  1.5 M Tris/HCl; pH8.8 
    0.2ml  10% (w/v) SDS 
    6.7ml  Acrylamide/Bisacrylamid 30%/0.8% (w/v) 
    0.2ml  Ammonium persulfate 10% (w/v) 
    0.008ml TEMED 
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5% Stacking gel  2.7ml  H2Odest. 
    0.5ml  1.0 M Tris/HCl; pH6.8 
    0.04ml 10% (w/v) SDS 
    0.67ml Acrylamide/Bisacrylamid 30%/0.8% (w/v) 
    0.04ml Ammonium persulfate 10% (w/v) 
    0.004ml  TEMED 
 
The protein solutions were heated at 95°C for 5min in Laemmli buffer and applied 
on a SDS polyacrylamid gel for protein fractionation by size at 35mA/150V (XCell 
SureLockTM Mini-Cell, Invitrogen, Karlsruhe, Germany). As size marker HiMark™ 
Pre-Stained High Molecular Weight Protein Standard (Invitrogen, Karlsruhe 
Germany) and peqGOLD Protein-Marker V (Peqlab, Erlangen, Germany) were 
used. 
4.9.4 Western Blotting 
Used buffers: 
Standard transfer buffer  10% (v/v) Methanol 
    25mM  Tris 
    190mM Glycine 
To detect the proteins after SDS-PAGE by use of specific antibodies proteins were 
transferred electrophoretically to a nitrocellulose membrane (Invitrogen, Karlsruhe, 
Germany) at 220mA/300 V for 1.5h (XCell II Blot Module, Invitrogen, Karlsruhe, 
Germany). To block unspecific binding sites, the membrane was bathed in TBST 
containing 5% BSA or 5% milk powder for 1h at RT. Then, the membrane was 
incubated with a specific primary antibody (Table 2) over night at 4°C. After 
washing with TBST, the membrane was incubated with a secondary horseradish 
peroxidase (HRP) conjugated antibody for 1h at RT. Thereafter, the membrane 
was washed and incubated with ImmunStarTM WesternCTM Kit (BioRad, München, 
Germany) for 3min. This system utilizes chemiluminescence, which was detected 
by the ChemiDoc XRS (BioRad, München, Germany) imaging system.  
Table 2 Antibodies used for Western Blot, immunohistochemistry and Western Blot 
Primary antibodies 
Antibody Dilution Company 
Actin 1:20000 Biomol, Hamburg, Germany 
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αsma 1:200 Abcam, Cambridge, UK 
MTAP 1:500 Abcam, Cambridge, UK 
survivin 1:1000 Abcam, Cambridge, UK 
phospho IκBα 1:1000 Cell signaling, Danvers, USA 
phospho p65 1:1000 Cell signaling, Danvers, USA 
Secondary antibodies 
anti rabbit Cy2 1:400 Dianova, Hamburg, Germany 
anti mouse TRITC 1:400 Dianova, Hamburg, Germany 
anti mouse HRP 1:3000 Santa Cruz, Heidelberg, Germany 
anti rabbit HRP 1:3000 Santa Cruz, Heidelberg, Germany 
 
4.9.5 Quantification of caspase-3/7 activity 
Caspases, or cysteine-aspartic acid proteases, are a family of cysteine proteases, 
which play essential roles in apoptosis. There are two types of apoptotic caspases: 
initiator (apical) caspases and effector (executioner) caspases. Initiator caspases 
(e.g. caspase-2, -8, -9, -10) cleave inactive pro-forms of effector caspases, 
thereby activating them. Effector caspases (e.g. caspase-3, -6, -7) in turn cleave 
other protein substrates within the cell, to trigger the apoptotic process. To analyze 
caspase-3/7 activity we used the Apo-One Homogeneous Caspase-3/7 Assay Kit 
(Promega, Mannheim, Germany) according to the manufacturer’s instructions. We 
used 6000 cells/well (96-well plate) and incubated cells with the provided caspase 
substrate Z-DEVD-R110 for 1h. Cleavage of the non-fluorescent caspase 
substrate Z-DEVD-R110 by caspase-3/7 liberates the fluorescent rhodamine 110, 
which was detected fluoro-spectrometrically with a SPECTRAFluor Plus 
microplate reader (Tecan, Männedorf, Switzerland) at wavelengths of 485nm 
(excitation) and 520nm (emission). Each experimental condition was performed in 
triplicates and experiments were repeated at least twice. 
4.9.6 5'-deoxy-5'-(methylthio)adenosine (MTA) extraction and analysis 
Medium was collected, centrifuged, and the supernatant was snap-frozen and 
stored at -80°C. Further, cell number in corresponding cell culture plates was 
determined by counting trypsinised cells. For intracellular MTA measurements, 
cells were harvested by incubation in a solution containing 0.05% (w/v) trypsin and 
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0.02% (w/v) EDTA. Trypsination was stopped after 5min with cell culture medium. 
Following centrifugation, the supernatant was removed, the cell pellet was washed 
with PBS, centrifuged again, snap-frozen and stored at -80°C. Samples were 
further processed by the Institute of Functional Genomics, University of 
Regensburg, as described in greater detail in (Stevens et al., 2010; Stevens et al., 
2008). Briefly, cell culture medium was spiked with stable isotope labeled MTA, 
dried by means of an infrared evaporator, and the residues reconstituted in 
0.1mol/l acetic acid. Frozen cell pellets were extracted by three repeated 
freeze/thaw cycles in 600µl of MeOH / 0.1mol/l acetic acid (80:20, v/v) after the 
addition of stable isotope labeled MTA. After centrifugation the supernatant was 
transferred in a glass vial and the protein pellet was washed twice with 
MeOH/acetic acid. The combined extracts were dried and reconstituted in 0.1mol/l 
acetic acid. Tissue samples were weighed and then homogenized in 600µl of 
MeOH/ 0.1mol/l aqueous acetic acid (80:20, v/v) using “Precelly-Keramik-Kit 
1.4mm” vials (Peqlab Biotechnologie GmbH, Erlangen, Germany). The samples 
were centrifuged at 9.000g for 5min at 4°C. Subsequently, the supernatant was 
transferred to a 1.5ml glass vial and the pellet was washed twice. After solvent 
evaporation, the residues were reconstituted in 0.1mol/l acetic acid. Liquid 
chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-
MS/MS) was carried out as described (Stevens et al., 2010). The analysis was 
performed using an Agilent 1200 SL HPLC system (Böblingen, Germany) and a 
PE Sciex API 4000 QTrap mass spectrometer (Applied Biosystems, Darmstadt, 
Germany). An Atlantis T3 3µm (2.1mm i.d.×150mm) reversed-phase column 
(Waters, Eschborn, Germany) was used. LC separation was carried out using a 
water-acetonitrile gradient consisting of 0.1% acetic acid and 0.025% HFBA in 
both solvents at a flow-rate of 400µl/min with an injection volume of 10µl. The API 
4000 QTrap mass spectrometer was operated in positive mode and quantitative 
determination was performed with multiple reaction monitoring (MRM). 
4.10  Flow cytometry 
4.10.1 Annexin V / Propidium iodide double staining 
At early stages of apoptosis cells change the structure of their membrane, which 
leads to the exposure of phosphatidylserine on the membrane surface. In living 
cells, phosphatidylserine is transported to the inside of the lipid bilayer by the 
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aminophospholipid translocase, a Mg2+ ATP dependent enzyme. At the onset of 
apoptosis, phosphatidylserine is translocated to the external membrane and 
serves as a recognition signal for phagocytes.  
Annexins are ubiquitous homologous proteins that bind phospholipids in the 
presence of calcium. Since the redistribution of phosphatidylserine from the 
internal to the external membrane surface represents an early indicator of 
apoptosis, Annexin V and its conjugates can be used for the detection of apoptosis 
because they interact strongly and specifically with exposed phosphatidylserine.  
The differentiation between apoptotic and necrotic cells can be performed by 
simultaneous staining with propidium iodide (PI), a dye that stains by intercalating 
into nucleic acid molecules. The cell membrane integrity excludes PI in viable 
cells, whereas necrotic cells are permeable to PI. Thus, dual parameter flow 
cytometric analysis allows for the discrimination between viable, early apoptotic 
and late apoptotic/necrotic cells.  
To quantify apoptotic cells we used the Annexin V-FITC Detection Kit (PromoKine, 
Heidelberg, Germany). Therefore, we resuspended 2 x 105 cells in 500µl of the 
provided binding buffer and added 5µl of the FITC-labeled Annexin V reagent and 
5µl of PI solution. After incubation for 5min at room temperature in the dark flow 
cytometric analysis was performed. The FITC-Annexin V signal was detected at a 
wavelength of 525 ± 12.5nm, the PI signal at a wavelength of 620 ± 12.5nm. The 
result of the dual parameter flow cytometric analysis were depicted as dotplot and 
evaluated by quadrant analysis. The y-axis of the dotplot shows PI fluorescent 
signal intensity, the x-axis FITC-Annexin V fluorescent signal intensity. 
Discrimination of viable, early apoptotic and late apoptotic/necrotic cells were done 
by means of different intensities of FITC-Annexin V of PI fluorescent signals. 
Viable cells show low FITC-Annexin V and PI fluorescence (lower left quadrant), 
early apoptotic cells show high FITC-Annexin V but low PI fluorescence (lower 
right quadrant) and late apoptotic/necrotic cells show both high FITC-Annexin V 
and PI fluorescence (upper right quadrant). 
To asses the effects of a specific apoptosis or necrosis inducing reagent the 
percental distribution of viable, early apoptotic and late apoptotic/necrotic cells 
related to the total of counted cell (104 cells) were calculated. 
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4.11 Measurement of reactive oxygen formation (ROS) 
Reactive oxygen species (ROS) formation was analyzed with an assays applying 
cell-permeant 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) according to 
the manufacturer's instructions (Invitrogen). Briefly, cells were incubated with 
H2DCFDA at a concentration of 100µM for 30min at 37°C, and after washing with 
PBS, ROS formation was detected using a multi-well fluorescence plate reader 
(Spectra Fuor Plus, Tecan, Männedorf, Switzerland) with excitation and emission 
filters of 485 and 535nm, respectively. 
4.12 Animal experiments 
4.12.1 BDL 
Experimental cholestasis induced by bile duct ligation (BDL) is a commonly used 
model of liver injury. BDL or sham surgeries were performed in 5 female C57Bl/6 
mice each as described (Gabele et al., 2009). After midline laparotomy the 
common bile duct was exposed and ligated. Then, the abdomen was closed again 
in layers. After 3 weeks, blood and livers were collected for further analysis.  
4.12.2 NASH 
Male BALB/c mice were purchased at 6 weeks of age, divided into two groups 
(n=5 each) and fed either with control diet or a non-alcoholic steatohepatitis 
(NASH) inducing high fat diet containing 30% lard, 1.25% cholesterol and 0.5% 
sodium cholate (Matsuzawa et al., 2007). After 30 weeks feeding animals were 
sacrificed and liver tissue was immediately frozen. 
4.13 Histology and Immunohistochemistry 
For histological and immunohistochemical analysis tissue was fixed for 24h in 
buffered formaldehyde solution (3.7% in PBS) at room temperature, dehydrated by 
graded ethanol and embedded in paraffin. Sections were cut at 5µm and stuck on 
glass slides.  
4.13.1 Histology and Immunohistochemistry 
Human liver biopsies were collected in the Molecular Pathology of the University 
Hospital Regensburg. The formalin-fixed and paraffin-embedded biopsies were 
dewaxed and rehydrated. The biopsies were then boiled for 30min in citrate buffer 
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(pH 6.0). Endogenous peroxidase activity was blocked in 3% v/v H2O2 in PBS for 
10min. The sections were placed in a humidified chamber and covered with 
blocking solution (Zytomed, Berlin, Germany) for 5min. Sections were incubated 
with primary anti-MTAP antibody in a 1:200 dilution in TBS–Tween (0.1% v/v) 
overnight at 4°C. After washing with TBS–Tween, sections were incubated with 
biotinylated secondary antibody for 20min (Zytomed), before incubation with 
Streptavidine-HRP conjugate for 20min and AEC (3-amino-9-ethylcarbazole) for 
30min (Zytomed) according to the manufacturers’ instructions.  
Deparaffinized sections were blocked with 1%BSA/PBS and incubated with anti 
MTAP and anti αsma antibody in 10% FCS and 1%BSA/PBS. After washing 
sections were incubated with Cy2- and TRITC conjugated secondary antibodies 
and a DAPI staining was performed to identify cellular nuclei. Images were 
collected by fluorescence microscopy using a Zeiss Axioskop2 mot plus 
microscope (Zeiss, Göttingen, Germany). 
4.13.2 Immunofluorescent cell staining 
For immunofluorescence analysis, 2 x 104 cells were seeded in permanox coated 
4-well chamber slides (Thermo Fisher Scientific, Karlsruhe, Germany) and 
cultured overnight. The following day, cells were fixed. Subsequently, cells were 
washed with PBS and fixed using 4% paraformaldehyd for 5 minutes. For 
permeabilization of cell membranes, 0.1% Triton X-100 (Sigma-Aldrich, Munich, 
Germany) was added for 15minutes. After two washing steps with PBS, a blocking 
solution (PBS and 5% BSA, w/v) was added for 30 ,minutes. Thereafter, cells were 
incubated with a MTAP antibody overnight at 4°C. Next day, cells were washed 
three times with PBS, followed by incubation with the secondary antibody 
(Invitrogen, Carlsbad, USA) for 1h. After extensively washing, hard set mounting 
medium including DAPI (Vector Laboratories, Burlingame, USA) was added and 
images were collected by fluorescence microscopy using a Zeiss Axioskop2 mot 
plus microscope (Zeiss, Göttingen, Germany). 
4.14 Statistical analysis 
Values are presented as mean ± SEM or mean ± SD as indicated. All experiments 
were repeated at least three times. Comparison between groups was made using 
the Student’s unpaired t-test. A p-value < 0.05 was considered statistically 
significant. Correlations were performed applying Pearson test. All calculations 
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were performed using the statistical computer package GraphPad Prism version 
4.00 for Windows (GraphPad Software, San Diego, CA, USA).  
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5 Results 
Our group could show that MTAP is downregulated in HCC and this 
downregulation results in an accumulation of the substrate MTA (Kirovski et al., 
2011). Further, in earlier studies we investigated the regulation of decreased 
MTAP expression in HCC which was mediated via hypermethylation of the MTAP 
promoter (Hellerbrand et al., 2006). Establishment of chronic liver disease can be 
seen as a deciding risk factor for developing HCC (Hernandez-Gea et al., 2013; 
White et al., 2012; Zhang and Friedman, 2012) so we wanted to unravel the role of 
MTAP in the progression of chronic liver disease. 
5.1 Expression and function of MTAP in chronic liver disease 
5.1.1 MTAP expression in chronic liver disease 
First, we analyzed hepatic tissue from patients with alcoholic liver disease and 
chronic viral infection and found significant lower MTAP mRNA and protein 
expression in liver cirrhosis compared to normal liver tissue (Figure 5.1).  
 
Figure 5.1 Analysis of MTAP mRNA and protein expression in normal (n=5) and cirrhotic 
(n=5) liver tissue by means of pRT-PCR and Western Blot. Actin served as loading 
control. (*p<0.05) 
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In line with the downregulation of MTAP, which catalyzes the phosphorylation of 
MTA, hepatic levels of this metabolite were significantly higher in cirrhotic 
compared to normal human liver tissue (Figure 5.2). 
 
Figure 5.2 Hepatic MTA levels of tissue of normal versus cirrhotic origin were determined 
by LC-ESI-MS/MS. (*p<0.05) 
5.1.2 MTAP expression in non-alcoholic steatohepatitis (NASH) 
Next, we assessed patients with non-alcoholic steatohepatitis (NASH), in which 
fibrosis was less advanced. Although MTAP mRNA and protein expression were 
similar as in normal hepatic tissue (Figure 5.3), MTA levels were significantly 
higher (Figure 5.4). 
 
Figure 5.3 Hepatic MTAP mRNA and protein levels of tissue of normal and NASH origin 
measured by pRT-PCR and Western Blot. Actin served as control for equal protein 
loading. 
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Figure 5.4 Hepatic MTA levels of hepatic tissue of normal and NASH origin by LC-ESI-
MS/MS. (*p<0.05) 
 
To verify these findings in experimental models of chronic hepatic injury, we 
analyzed MTAP expression in mice subjected to three weeks bile duct ligation 
(BDL) or fed with a NASH-inducing diet for 30 weeks. Similar as in human 
cirrhosis, MTAP mRNA and protein expression were significantly reduced in the 
BDL model (Figure 5.5). 
 
Figure 5.5 MTAP mRNA and protein expression in mice subjected to BDL (n=5) and 
control mice (n=5). (*p<0.05) 
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In murine NASH-livers MTAP expression was neither affected on mRNA nor on 
protein level (Figure 5.6). However, hepatic MTA levels were significantly higher in 
murine NASH livers (Figure 5.7) paralleling the findings in human NASH. 
 
Figure 5.6 MTAP mRNA and protein expression in mice which were fed a NASH inducing 
diet (n=5) versus control mice (n=5). 
 
 
Figure 5.7 Hepatic MTA levels in mice which were fed a NASH inducing diet versus 
control mice. (*p<0.05) 
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5.2 MTAP expression in hepatic stellate cells 
Immunohistochemical analysis revealed reduced MTAP expression in hepatocytes 
in both human cirrhotic liver tissue (Figure 5.8 II) and murine BDL-livers (Figure 
5.9). In contrast, myofibroblast-like cells in fibrotic septa showed a strong MTAP 
immunosignal (Figure 5.8 panel III).  
 
Figure 5.8 Immunohistochemical analysis of MTAP in ctrl. (panel I) and cirrhotic (II, III) 
human liver tissue (Magnifications I (200x) and II (400x)). Myofibroblast like cells in fibrotic 
septa revealed a strong MTAP immunosignal (III). 
 
Figure 5.9 Immunohistochemical analysis of MTAP in ctrl. (panel I) and fibrotic (II) murine 
liver tissue (Magnification 200x).  
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Also in vitro activated hepatic stellate cells (HSCs) revealed higher MTAP 
expression than primary human hepatocytes (PHHs) (Figure 5.10). Still, 
hepatocytes constitute the bulk mass of hepatic cells in healthy as well as in 
diseased livers, and thus, reduced MTAP expression in these cells likely accounts 
for reduced MTAP levels observed in fibrotic liver tissues. Furthermore, lowered 
MTAP in hepatocytes appeared as one probable reason for increased MTA levels 
in diseased livers.  
 
 
Figure 5.10: Measurement of MTAP mRNA and protein levels in primary human 
hepatocytes (PHHs) and activated HSCs. In Western Blot analysis actin was used to 
demonstrate equal protein loading. (*p<0.05) 
 
However, MTA levels were strikingly higher in activated HSCs compared to PHHs 
in vitro (Figure 5.11), and MTA levels correlated significantly with collagen I 
mRNA expression in diseased human liver tissue (Figure 5.12).  
 
 
Figure 5.11: Measurement of intracellular MTA with LC-ESI-MS/MS in primary human 
hepatocytes (PHHs) and activated HSCs.  
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Further, we could show a colocalization of MTAP and αsma in hepatic sections of 
fibrotic liver tissue (Figure 5.13). As described in chapter 3.2, hepatic stellate cells 
express collagen I and αsma which can be considered markers of fibrosis.  
 
Figure 5.12 Correlation of hepatic MTA content, measured with LC-ESI-MS/MS and 
hepatic Collagen I expression measured with pRT-PCR. 
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Figure 5.13 Immunofluorescent staining of αsma (red) and MTAP (green) and αsma and 
MTAP (merge) in fibrotic murine livers. Dapi staining (blue) identifies cellular nuclei. 
(Magnifications: I (x200), II (x400), III (x800)) 
 
Together these findings indicated that activated HSCs significantly contribute to 
elevated MTA levels and MTAP expression in diseased livers. Higher expression 
of both MTAP expression and MTA levels in activated HSCs compared to 
hepatocytes might be explained by a generally more active methionine and 
adenine salvage pathway in response to high proliferation and cellular 
transdifferentiation in activated HSCs. Furthermore, these findings may explain the 
observed increase in MTA levels in murine and human NASH tissues despite 
unaltered MTAP expression (Figure 5.3, Figure 5.4, Figure 5.6, Figure 5.7). 
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5.3 Functional role of MTAP in activated hepatic stellate cells 
5.3.1  Functional role of MTAP suppression 
To get an insight into the functional role of MTAP in HSCs, we transiently 
transfected activated HSCs with siRNA directed against MTAP, which led to 
significantly reduced MTAP mRNA and protein expression compared to HSCs 
transfected with control siRNA (Figure 5.14).  
 
 
Figure 5.14 Activated HSCs were transfected with siRNA against MTAP (siRNA1 and 
siRNA2) or control siRNA. Analysis of MTAP downregulation on mRNA by pRT-PCR and 
protein level in MTAP siRNA treated activated HSCs via Western Blot and 
immunofluorescence. Actin staining confirms equal loading in Western Blot. 
Immunofluorescent staining of MTAP protein (green) in MTAP siRNA transfected HSCs, 
DAPI identified cellular nuclei (blue). (*p<0.05) 
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Furthermore, MTAP suppression led to increased MTA levels in activated HSCs 
(Figure 5.15). 
 
Figure 5.15 Analysis of intracellular MTA in activated HSCs treated with MTAP siRNA by 
means of LC-ESI-MS/MS. (*p<0.05) 
 
We have previously shown that MTA affects NFκB activity in hepatocellular 
carcinoma (Kirovski et al., 2011), and thus, we assessed whether this signaling 
pathway is also affected by MTA in activated HSCs. MTAP suppressed HSCs 
revealed higher levels of phosphorylated p65 (Figure 5.16 A) indicative of 
increased NFκB activation. Further, a NFκB reporter gene assay (Figure 5.16 B) 
revealed increased NFκB activity in MTAP suppressed cells.  
 
Figure 5.16 Effect of MTAP suppression on NFκB signaling: phospho p65 (A). Actin 
demonstrated equal protein loading. NFκB reporter gene assay (pGL3: empty vector) (B). 
(*p<0.05) 
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The NFκB signaling pathway is increased during the activation of HSCs and 
protects these cells from apoptosis (Elsharkawy et al., 2005; Hellerbrand et al., 
1998). Consequently, analysis of caspase3/7 activity (Figure 5.17 A) and FACS 
analysis (Figure 5.17 B) revealed that HSCs with suppressed MTAP expression 
were less susceptible for staurosporine (STS) induced apoptosis compared to 
control siRNA transfected cells.  
 
Figure 5.17 Analysis of caspase 3/7 activity after induced apoptosis (Staurosporine (STS) 
500nM; 4h) (A). Assessment of STS-induced apoptosis by flow cytometric analysis of 
annexin V-FITC / propidium iodide stained cells. Depicted are the mean percentages of 
total apoptotic cells from 3 independent experiments. (*p<0.05 compared to ctrl. siRNA) 
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In a second approach we enhanced MTAP expression in activated HSCs by 
transient transfection with a MTAP-expression plasmid (Figure 5.18).  
 
Figure 5.18 Activated HSCs were transiently transfected with control vector (pcDNA3) and 
an MTAP expression vector (MTAP). Analysis of MTAP expression by pRT-PCR and 
Western Blot. (*p<0.05) 
 
Consequently, MTAP overexpressing HSCs revealed reduced MTA levels (Figure 
5.19), reduced p65-phosphorylation (Figure 5.20 A) and NFκB reporter gene 
activity (Figure 5.20 B).  
 
 
Figure 5.19 Quantification of cellular MTA levels by LC-ESI-MS/MS in activated HSCs 
transiently transfected with control vector (pcDNA3) and MTAP expression vector (MTAP). 
(*p<0.05) 
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Figure 5.20 Effect of MTAP overexpression on NFκB signaling: phospho p65 Western Blot 
(A) as well as NFκB reporter gene assay (pGL3: empty vector) (B). (*p<0.05) 
 
Furthermore, elevated MTAP expression made HSCs more susceptible for STS 
induced apoptosis (Figure 5.21) than control vector (pcDNA3) transfected cells. 
Together, these data indicate that MTAP expression is a critical regulator of MTA 
levels in activated HSCs, and herewith significantly affects NFκB activity and 
apoptosis in HSCs. 
 
 
Figure 5.21 Functional effect of MTAP overexpression on resistance towards apoptosis in 
MTAP overexpressing activated HSCs: Analysis of caspase3/7 activity (A) after induced 
apoptosis (Staurosporine (STS) 500nM; 4h) and (B) assessment of STS induced 
apoptosis by cytometry applying annexin V and propidium iodide staining. Depicted is 
mean-percentage of total apoptotic cells from 3 independent experiments. (*p<0.05 
compared to pcDNA3) 
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5.4 Effect of MTA on hepatic stellate cells 
5.4.1 During activation 
The activation of hepatic stellate cells is the key event in the progression of 
chronic liver disease. We wanted to know whether stimulation of HSCs during the 
course of activation influences profibrogenic gene expression. Markers of HSC 
activation αsma and Collagen I were further increased with MTA stimulation 
(Figure 5.22). 
 
Figure 5.22: Profibrogenic gene expression of αsma (A) and Collagen I (B) in HSCs 
stimulated with MTA during activation. (*p<0.05) 
5.4.2 In activated HSCs 
Loss and gain of function studies indicated that MTAP regulated MTA levels 
exhibit profibrogenic effects on HSCs. In contrast, previous studies by Simile et al. 
and Latasa et al. showed that MTA stimulation in a dose range between 25µM and 
500µM or 200µM and 500µM, respectively, caused impaired fibrogenic 
characteristics of activated HSCs (Latasa et al., 2010; Simile et al., 2001). To 
unravel these putative discrepancies we stimulated activated HSCs with MTA in a 
wide dose range comprising MTA levels found in diseased murine and human liver 
tissues (up to 5µM) and MTA doses as high as 1mM. In concentrations up to 5µM 
MTA stimulation led to dose-dependent induction of CCL5 (also called RANTES 
(Regulated on Activation, Normal T cell Expressed and Secreted)) and CCL2 (also 
referred to as monocyte chemotactic protein-1 (MCP-1)) expression, while higher 
MTA doses reduced the expression of both chemokines in activated HSCs (Figure 
5.23, Figure 5.24). These findings indicated a nonmonotonic dose-response 
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relationship between MTA levels and profibrogenic gene expression in activated 
HSCs. While the studies of Simile et al. and Latasa et al. (Latasa et al., 2010; 
Simile et al., 2001) comprehensively assessed the effects of exogenously applied 
MTA doses, we subsequently focused on the assessment of the effects of 
(endogenous) MTA levels found in diseased livers. In this dose range, MTA 
caused a time-dependent induction of CCL5 (Figure 5.23) expression in activated 
HSCs in vitro.  
 
Figure 5.23: Dose (A) and time (MTA 1µM) (B) dependent proinflammatory gene 
expression of CCL5 in activated HSCs treated with MTA. (*p<0.05) 
 
 
Figure 5.24: Dose dependent induction of CCL2 mRNA in activated HSCs treated with 
MTA. (*p<0.05) 
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Rapid induction of chemokine expression pointed to an effect on transcriptional 
regulation, and NFκB is a known critical regulator of these chemokines (Mezzano 
et al., 2004). MTA stimulation of HSCs induced a dose-dependent phosphorylation 
of IκBα (Figure 5.25) and activation of NFκB-reporter gene activity (Figure 5.25). 
Moreover, analysis of caspase3/7 activity and FACS analysis revealed, that MTA 
stimulation increased the resistance of activated HSCs towards apoptosis (Figure 
5.26).  
 
 
Figure 5.25: Induction of NFκB in activated HSCs treated with MTA (1µM) measured with 
phospho IκBα Western Blot (A) and a NFκB reporter gene assay (pGL3= empty vector) 
(B). (*p<0.05) 
 
Figure 5.26 Reduced resistance towards STS induced apoposis in MTA (1µM) treated 
activated HSCs. (*p<0.05) 
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5.4.3 Functional effect of MTAP/MTA on survivin expression in 
activated hepatic stellate cells 
Manipulation of MTAP expression or MTA stimulation did not significantly affect 
BAX, BCLXL and XIAP expression in activated HSCs (Figure 5.27).  
 
 
 
Figure 5.27 Expression of apoptosis related genes in MTAP manipulated and MTA treated 
activated HSCs. Quantitative RT-PCR analysis of BAX, BCLXL, and XIAP mRNA 
expression in activated HSCs (A) transfected with MTAP siRNA or control siRNA, (B) 
stimulated with MTA, and (C) transfected with MTAP expression plasmid or control vector 
(pcDNA3) . 
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However, MTAP suppressed cells (Figure 5.28 A) and wildtype HSCs stimulated 
with MTA (Figure 5.28 B) revealed an increased expression of survivin. In 
contrast, survivin expression was downregulated in MTAP overexpressing HSCs 
compared to pcDNA3 transfected control cells (Figure 5.28 C).  
 
Figure 5.28 Survivin mRNA and protein expression in activated HSCs (A) transfected with 
MTAP siRNA or control siRNA, (B) stimulated with MTA, and (C) transfected with an 
MTAP expression plasmid or empty vector (pcDNA3). (*p<0.05) 
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Survivin is a target of NFκB (Basseres and Baldwin, 2006) and can prevent 
caspase-induced apoptosis (Tamm et al., 1998). This suggested that the 
regulation of this anti-apoptotic factor accounts at least in part for the effects of the 
manipulation of MTAP levels and MTA stimulation, respectively, on apoptosis 
resistance of HSCs. Accordingly, pretreatment with the survivin inhibitor YM-155 
abolished the apoptosis protecting effect of MTA stimulation in HSCs (Figure 
5.29). In summary, these findings indicated, that NFκB-mediated regulation of 
survivin expression was responsible for the effects of MTAP and MTA on 
apoptosis resistance of activated HSCs. 
 
Figure 5.29 Assessment of caspase3/7 activity in MTA-treated HSCs with and without 
preincubation with the survivin inhibitor YM155 (5µM) following staurosporine (500nM; 4h) 
induced apoptosis. 
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5.4.4 Role of methylation and the generation of reactive oxygen 
species (ROS) on MTAP regulation in activated HSCs 
Next, we analyzed the mechanisms regulating MTAP expression in activated 
HSCs. Previously, we have shown that promotor methylation causes 
downregulation of MTAP expression in HCC (Hellerbrand et al., 2006), and 
Ramani et al. described decreased global DNA methylation during HSC activation 
(Ramani et al., 2010). To assess whether this mechanism also affects MTAP 
expression in HSCs, we incubated activated HSCs with the demethylating agent 5-
azacytidine (5-Aza) and found that this treatment further enhanced MTAP 
expression in a dose dependent manner (Figure 5.30).  
 
Figure 5.30 Analysis of MTAP mRNA in activated murine HSCs stimulated with 5-
azacytidine (1-100µM). (*p<0.05) 
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Liver damage, which leads to HSC activation, is characterized by increased 
reactive oxygen species (ROS) formation, and oxidative stress has been shown to 
induce promoter methylation (Min et al., 2010; Ziech et al., 2011). Arsenic trioxide 
(AT) induces ROS production via up-regulation of NADPH oxidase (Chou et al., 
2004) (Figure 5.31 A, B). Furthermore, we analyzed expression of heme 
oxygenase (decycling) 1 (HMOX). HMOX is an essential enzyme in heme 
catabolism, it cleaves heme to form biliverdin and is increased via induction of 
ROS (Figure 5.31 C) (Jaeschke, 2011; Tanaka et al., 2007). 
 
Figure 5.31. A dichlorodihydrofluorescein diacetate (H2DCFDA) assay confirmed induced 
ROS formation in AT (10µM) treated HSCs (A). Analysis of p47phox mRNA (B) and 
HMOX (heme oxygenase (decycling) 1) (C) expression in AT (10µM) treated HSCs. 
(*p<0.05) 
 
Treatment of activated HSCs with AT downregulated MTAP expression (Figure 
5.32).  
 
Figure 5.32 MTAP mRNA and protein expression in activated HSCs treated with As2O3 
(AT) and NAC (10mM). (*p<0.05) 
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Preincubation with the ROS-scavenger N-Acetyl- L-Cysteine (NAC) abrogated AT 
induced downregulation of MTAP mRNA and protein (Figure 5.32). Also 
stimulation with hydrogen peroxide (H2O2) dose dependently downregulated 
MTAP in HSCs while HMOX and p47phox are induced (Figure 5.33) confirming 
that oxidative stress caused a downregulation of MTAP in HSCs.  
 
Figure 5.33 Activated HSCs were treated with different doses of hydrogen peroxide (H2O2) 
and quantification of (A) MTAP (B) HMOX1 (heme oxygenase (decycling) 1 and (C) 
p47phox mRNA expression was performed with quantitative RT-PCR. (*p<0.05) 
 
In contrast, pretreatment with methyltransferase inhibitor adenosine periodate 
oxidized (AdOx) abolished ROS induced MTAP downregulation (Figure 5.34).  
 
 
Figure 5.34 Analysis of MTAP mRNA in activated murine HSCs stimulated with 10µM 
As2O3 (AT), AdOx (50µM) alone and in combination with AT. (*p<0.05 compared to ctrl.; 
#p<0.05 compared to AT) 
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On the contrary, AT stimulation increased survivin expression in activated HSCs, 
and this induction was blunted by AdOx treatment (Figure 5.35). Together, these 
data indicate that epigenetic mechanisms account at least in part for the increased 
MTAP expression during HSC activation, while oxidative stress causes a 
downregulation of MTAP expression in activated HSCs, and herewith functionally 
affects the profibrogenic phenotype of these cells. 
 
Figure 5.35 Survivin mRNA expression in activated HSCs treated with As2O3 (AT) (10µM) 
and methylation inhibitor AdOx (50µM) alone and in combination with AT. (*p<0.05 
compared to ctrl.; #p<0.05 compared to AT) 
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6 Discussion 
Recently, we have shown downregulation and tumor suppressor activity of MTAP 
in hepatocellular carcinoma (HCC) (Kirovski et al., 2011). Here, we expanded our 
investigation on chronic liver disease, which is the major HCC precondition 
(Hernandez-Gea et al., 2013; White et al., 2012; Zhang and Friedman, 2012). The 
observed downregulation of MTAP mRNA expression in cirrhotic human livers and 
experimental models of liver cirrhosis was in line with a previous study by Berasain 
et al. (Berasain et al., 2004). Here, we confirmed this finding at the protein level, 
and applying immunohistochemistry we revealed that hepatocytes of cirrhotic 
livers have lower MTAP expression than hepatocytes in normal liver tissue. In 
contrast, we found strong MTAP expression in activated HSCs in cirrhotic livers. 
Moreover, we demonstrated that not only MTAP but also its metabolite MTA are 
abundant in activated HSCs. This may be caused by an upregulation of polyamine 
biosynthesis in response to enhanced proliferation and cellular transdifferentiation 
during the course of HSC activation. In line with this, activated HSCs showed 
markedly higher MTA levels than hepatocytes in vitro. Moreover, hepatic MTA 
levels strongly correlated with collagen I expression in diseased hepatic tissue. 
And further, MTAP expression is colocalized with αsma. Together these findings 
indicated that also in vivo activated HSCs significantly contribute to MTA 
abundance in fibrotic livers despite their relatively lower quantity compared to 
hepatocytes, which are the main cellular source of total MTA in normal liver tissue. 
Differences in the cellular sources of MTAP and MTA could also account for 
enhanced MTA levels in NASH, although MTAP levels in total liver tissue were 
similar as in normal liver tissue. Furthermore, this may be an explanation why 
Berasain et al. did not find MTA accumulation in the model of carbon tetrachloride 
(CCl4)-induced liver injury in spite of a compromised expression of MTAP 
(Berasain et al., 2004). In addition, it has to be considered that MTA is produced 
during polyamine biosynthesis from S-adenosylmethionine (AdoMet, SAM), its 
metabolic precursor. Interestingly, Berasain et al. found that AdoMet was strongly 
reduced in CCl4-treated rats, and herewith, identified one further potential 
mechanism why reduced MTAP levels in diseased livers may not always coincide 
with lowered MTA levels in particular experimental models. 
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In the present study, we observed increased MTA levels in two experimental 
models of hepatic injury as well as in patients with NASH and cirrhosis of different 
origin. We could show that treatment of HSCs during in vitro activation with 
physiologic relevant doses of MTA enhanced profibrogenic gene expression. 
Beyond, stimulation of activated HSCs with MTA at concentrations similar to those 
found in diseased liver tissues caused increased proinflammatory gene expression 
and NFκB activation, as well as enhanced apoptosis resistance. In contrast to our 
findings, some groups have reported proapoptotic effects of MTA on hepatoma 
cells (Ansorena et al., 2002), and found antifibrotic effects of MTA on HSCs in vitro 
and in experimental models of hepatic fibrosis (Latasa et al., 2010; Simile et al., 
2001). However, in those studies significantly higher, pharmacological doses had 
been administered, whereas the MTA levels achieved here mirrored endogenous 
hepatic levels. Moreover, pharmacological doses of MTA have been shown to 
exhibit protective effects on hepatocytes in vitro (Ansorena et al., 2006; Ansorena 
et al., 2002; Hevia et al., 2004), while MTA accumulation in HCC promotes 
tumorigenicity (Kirovski et al., 2011). Our in vitro findings clearly showed a 
biphasic effect of MTA stimulation levels on profibrogenic response in activated 
HSCs, and it is reasonable that also in other cells such a nonmonotonic dose-
response relationship exists. Together, these findings indicate that hepatic effects 
of MTA are a double-edged sword and warrant the exercise of caution in the 
pharmacological use of MTA in treating liver disease, as pharmacological levels 
may drop to levels at which pro-fibrogenic and pro-tumorigenic effects 
predominate.  
In addition to exogenous MTA stimulation also manipulation of MTAP expression 
and subsequent alterations of intracellular MTA levels functionally affected 
activated HSCs. Survivin has been described as a NFκB target gene in tumor cells 
(Basseres and Baldwin, 2006), and De Minicis et al. described increased survivin 
expression in HSCs isolated from murine fibrosis models (De et al., 2007). Here, 
we showed that survivin functionally affected apoptosis resistance of activated 
HSCs and identified this member of the Inhibitor of Apoptosis (IAP) family as a 
transcriptional target of exogenous MTA mediated NFκB activation in activated 
HSCs. Moreover, loss and gain of function studies revealed that MTAP-regulated 
levels of intracellular MTA affect NFκB activity and survivin expression in activated 
HSCs. NFκB activity in HSCs is critical for their resistance against apoptosis, and 
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herewith, the extent of fibrosis in chronic liver injury (Wright et al., 2001). Hepatic 
fibrosis and cirrhosis are HCC preconditions, and we have shown downregulation 
and tumor suppressor activity of MTAP in HCC (Kirovski et al., 2011). Together, 
these findings suggest (induction of) MTAP as therapeutic strategy against both 
fibrosis and cancerogenesis in chronic liver disease. Noteworthy, we found that 
promoter methylation is a critical regulator of MTAP expression in HSCs similar as 
we and others have shown before in HCC cells (Berasain et al., 2004; Hellerbrand 
et al., 2006). DNA methylation inhibitors have been suggested for treatment of 
HCC (Sceusi et al., 2011) and have been shown to inhibit HSC activation and 
fibrogenesis (Mann et al., 2007). Our study unraveled a novel mechanism by 
which epigenetic mechanisms critically affect the fibrogenic potential of HSCs. 
Furthermore, we identified oxidative stress to impair MTAP expression in HSCs. 
This finding is complementary to a previous study by Fernandez-Irigoyen et al., 
who demonstrated redox regulation of MTAP activity in hepatocytes (Fernandez-
Irigoyen et al., 2008). 
In conclusion, we identified regulation of MTAP expression and corresponding 
MTA levels as a novel mechanism affecting profibrogenic gene expression, NFκB 
activity and apoptosis resistance in HSCs. This may be exploited for the prognosis 
or treatment of fibrosis progression in chronic liver disease. 
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8 Abbreviations 
AEC 3-amino-9-ethylcarbazole 
AMP adenosine monophosphate 
AdoMet S-adenosyl- L -methionine 
AdOx adenosine-2′,3′-dialdehyde, adenosine 
periodate oxidized 
ALF acute liver failure 
AMV-RT avian myeloblastosis virus reverse 
transcriptase 
AOM/DSS azoxymethane/ dextran sodium 
sulphate 
APS ammonium persulfate 
As2O3 arsenic trioxide 
AT arsenic trioxide 
ATP adenosine triphosphate 
Aza 5-Azacytidine 
BCA bicinchoninic acid  
BDL bile duct ligation 
Bp base pairs 
BSA bovine serum albumin 
ca. circa 
cAMP cyclic adenosine monophosphate 
CCl4 carbon tetrachloride 
CCL5 chemokine Ligand 5 = RANTES 
(Regulated on Activation, Normal T cell 
Expressed and Secreted) 
CCL2 chemokine ligand 2 = MCP-1 
(monocyte chemotactic protein-1) 
cDNA complementary DNA 
Coll I Collagen I 
Ctrl. control 
Cy2 Cyanine dye 2 
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Da dalton (=1.66018 x 10-24 g) 
DAPI 4’, 6-diamino-2-phenylindole 
DMEM Dulbecco’s modified eagle medium 
DNA deoxyribonucleic acid 
e.g. exempli gratia 
ECM extracellular matrix 
EDTA ethylene diamine tetraacetic acid 
et al. et alii 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
g gram 
h hour 
H2DCFDA 2',7'-dichlorodihydrofluorescein 
diacetate 
H2Odest. destilled water 
HCC hepatocellular carcinoma 
HMOX heme oxygenase (decycling) 1 
HRP horse radish peroxidase 
HSC(s) hepatic stellate cell(s) 
IAP Inhibitor of Apoptosis 
Ig immunoglobulin 
IκBα inhibitory kappa B alpha 
kDa kilodalton 
l liter 
LC-ESI- MS/MS liquid chromatography-electrospray 
ionization-tandem mass spectrometry 
LPS Lipopolysaccharides 
M molar, mol/l 
mA milliampere 
MCP-1 monocyte chemoattractant protein-1 = 
CCl2 
mg milligram 
min minute 
Abbreviations  80 
ml milliliter 
mM millimolar 
mm millimeter 
mmol millimol 
MMPs matrix metalloproteinase 
mRNA messenger RNA 
MTA 5'-deoxy-5'-(methylthio)adenosine 
MTAP methylthioadenosine phosphorylase 
MTOB 4-methylthio-2-oxobutanoic acid 
MTR-1P methylthioribose 1-phosphate 
NAC N-Acetyl- L-Cysteine 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
NFκB nuclear factor kappa B 
ng nanogram 
ODC ornithine decarboxylase 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pH pondus hydrogenii 
PHHs primary human hepatocytes 
PI propidium iodide 
qRT-PCR quantitative realtime-PCR 
RANTES Regulated on Activation, Normal T cell 
Expressed and Secreted = CCl5 
ROS reactive oxygen species 
rpm rounds per minute 
RT room temperature 
s second 
SAM S-adenosyl- L -methionine 
SDS sodium dodecyl sulfate 
STS staurosporine 
TBS tris-buffered saline 
TE tris EDTA 
Abbreviations  81 
TEMED N, N, N’, N’-tetramethylethylenediamine 
TIMP tissue inhibitors of matrix 
metalloproteinases 
Tris tris(hydroxymethyl)aminomethane 
TRITC isothiocyanate derivative 
Tween Polyoxyethylene sorbitan monolaurate 
UK United Kingdom 
USA United States of America 
µg microgram 
µl microliter 
µm microgram 
µM micromolar 
°C degree Celsius 
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9 Appendix 
9.1 Curriculum vitae 
Diplom Biologin Barbara Czech 
 
Adresse Straubinger Straße 19 
 93055 Regensburg 
geboren am 15.10.1983 in Simbach am Inn 
Familienstand ledig 
Konfession römisch-katholisch 
Staatsangehörigkeit deutsch 
seit 09/2009 Promotion als wissenschaftlicher Mitarbeiter am 
Universitätsklinikum Regensburg in der Abteilung Innere Medizin I 
in der Arbeitsgruppe von Prof. Dr. Claus Hellerbrand. 
07/2009 Diplom im Fach Biologie: Hauptfächer: Zellbiologie, Biochemie, 
Tierphysiologie 
Bewertung: sehr gut 
10/2008-07/2009 Diplomarbeit am Lehrstuhl für zelluläre und molekulare 
Neurobiologie von Prof. Dr. Inga Neumann: „Auswirkungen von 
Oxytocin auf die Emotionalität bei Ratten.“ 
10/2003-07/2009 Studium der Biologie an der Universität Regensburg 
07/2003 Abitur am Gymnasium in Pfarrkirchen 
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9.2 Advanced training and courses 
2010 Teilnahme an der Weiterbildungsveranstaltung 
„Versuchstierkunde und Tierschutz (nach den FELASA-B – 
Richtlinien)“ am Universitätsklinikum Regensburg 
03/2010 Teilnahme an der „Fortbildungsveranstaltung für Projektleiter 
und Beauftragte für Biologische Sicherheit (BBS)“ am 
Universitätsklinikum Regensburg 
27.-28.01.2011 Falk Workshop Liver and Immunology 
26.-27.01.2012 Falk Work Inflammation and Cancer 
24.-25.02.2013 Falk Work Targeted Therapies in Hepatology 
 
9.3 Publications 
2013 
1. Czech B, Neumann ID, Müller M, Reber SO, Hellerbrand C  
Combination of chronic psychosocial stress and a NASH inducing diet in mice 
International Journal of Clinical and Experimental Pathology 2013 
2012 
2. Valletta D, Czech B, Thasler WE, Müller M, Bosserhoff AK, Hellerbrand C 
Expression and function of the atypical cadherin FAT1 in chronic liver disease 
Biochemical and Biophysical Research Communications 2012  
3. Saugspier M, Dorn C, Czech B, Gehrig M, Heilmann J, Hellerbrand C.  
Hop bitter acids inhibit tumorigenicity of hepatocellular carcinoma cells in vitro 
Oncology Reports 2012  
2011 
4. Schnabl B, Czech B, Valletta D, Weiss TS, Kirovski G, Hellerbrand C 
Increased expression of zinc finger protein 267 in non-alcoholic fatty liver 
disease 
International Journal of Clinical and Experimental Pathology 2011 
5. Kirovski G, Stevens AP, Czech B, Dettmer K, Weiss TS, Wild P, Hartmann A, 
Bosserhoff AK, Oefner PJ, Hellerbrand C. 
Down-regulation of methylthioadenosine phosphorylase (MTAP) induces 
progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-
methylthioadenosine (MTA) 
American Journal of Pathology 2011 
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9.4 Presentations 
Symposium: Tumor Metabolism meets Immunology (2013, Regensburg) 
 Czech B, Valletta D, Saugspier M, Müller M, Bosserhoff AK, Hellerbrand C 
Effect of increased glucose transporter 1 (GLUT1) expression in activated 
hepatic stellate cells 
29. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der 
Leber (2013, Hannover) 
 Czech B, Valletta D, Dettmer K, Müller M, Bosserhoff AK, Oefner PJ, 
Hellerbrand C 
Downregulation of methylthioadenosine phosphorylase (MTAP) expression in 
chronic liver disease promotes hepatic inflammation and fibrosis 
 Czech B, Valletta D, Saugspier M, Müller M, Bosserhoff AK, Hellerbrand C 
Effect of increased glucose transporter 1 (GLUT1) expression in activated 
hepatic stellate cells 
 Czech B, Weigand K, Neumann ID, Müller M Reber SO, Hellerbrand C 
Combination of psychosocial stress and a NASH-inducing diet in mice  
Falk Workshop Targeted Therapies in Hepatology (2013, Hannover) 
 Czech B, Hellerbrand C 
Upregulation of Myc-associated zinc finger protein (MAZ) in the pathogenesis 
of chronic liver disease 
47th Annual Meeting of the European Association for the Study of the Liver 
(2012, Barcelona) 
 Czech B, Valletta D, Saugspier M, Dettmer K, Weiss TS, Bosserhoff AK, 
Oefner PJ, Hellerbrand C 
Downregulation of methylthioadenosine phosphorylase (MTAP) expression in 
chronic liver disease promotes hepatic inflammation and fibrosis 
28. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der 
Leber (2012, Hamburg) 
 Czech B, Valletta D, Hellerbrand C 
Increased expression of the glucose transporter GLUT1 in liver fibrosis  
 Czech B, Valletta D, Saugspier M, Dettmer K, Weiss TS, Bosserhoff AK, 
Oefner PJ, Hellerbrand C 
Downregulation of methylthioadenosine phosphorylase (MTAP) expression in 
chronic liver disease promotes hepatic inflammation and fibrosis 
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Falk Workshop Inflammation and Cancer (2012, Hamburg) 
 Czech B, Valletta D, Hellerbrand C 
Monoacylglycerol lipase (MAGL) is downregulated in hepatocellular 
carcinoma  
27. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der 
Leber (2011, Regensburg) 
 Czech B, Kirovski G, Stevens AP, Saugspier M, Dorn C, Bosserhoff AK, 
Oefner PJ, Hellerbrand C 
Expression and function of methylthioadenosine phosphorylase (MTAP) in 
chronic liver disease 
 
9.5 Awards/ Grants 
 Falk Foundation Travel Award 2013, Hannover, Germany 
 EASL (European Association for the Study of the Liver) Travel Award 2012, 
Barcelona, Spain 
 Falk Foundation Travel Award 2012, Hamburg, Germany 
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